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LIST OF ABBREVIATIONS 
CNS Central nervous system 
MS Multiple sclerosis 
ADEM Acute-disseminated encephalomyelitis 
AHL Acute haemorrhagic leucoencephalitis 
PML Progressive multifocal leucoencephalopathy 
CPM Central pontin myelinolysis 
EPM Extrapontin myelinolysis 
LA Leukoaraiosis 
MRI Magnetic Resonance Imaging 
MTHFR Methylene tetrahydrofolate reductase 
ACE Angiotensin-converting enzyme 
APOE Apolipoprotein E 
AQP-4 Aquaporin-4 
CADASIL Cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy 
NMSS National Multiple Sclerosis Society 
RR Relapsing-remitting  
SP Secondary progressive 
PP Primary progressive 
PR Progressive relapsing 
CIS Clinically isolated syndrome 
EDSS Expanded Disability Status Scale 
GWAS Genome-wilde association studies 
IL Interleukine 
TNF Tumor necrosis factor 
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AMPs Antimicrobial peptides 
hBDs Human β-defensins  
HBD1, HBD2 Human beta defensin-1, -2 
UTR Untranslated region 
PCR Polymerase chain reaction 
RT-PCR Real time polymerase chain reaction 
CT Threshold cycle 
ELISA Enzyme linked immunosaorbent assay 
SNPs Single nucleotide polymorphisms 
CNPs Copy number polymorphisms 
CNVs Copy number variations 
AD Alzheimer’s disease 
Abeta Amyloid β 
eFAD Early onset familial AD  
LOAD Late-onset AD  
SPECT Single photon emission computed 
tomography 
DSM-IV Fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders 
NINCDS–ADRDA  
MMSE Mini-Mental State Exam 
ADAS-Cog AD Assessment Scale – Cognitive Subscale  
CDT Clock Drawing Test 
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1.INTRODUCTION 
1.1 Definition of the demyelinating disorders 
Demyelinating diseases are characterized by the loss of the normal myelin 
denvelopment and integrity. 1 Demyelination may attack axons in the central and peripherial 
nervous system and it creates a variety of neurological disorders and syndromes. 2 
1.1.1 Classification of the CNS demyelination  
The classification of the CNS demyelination is complicated. However, it can be 
classified according to the pathogenesis of the disease. Inflammatory demyelination, 
demyelination due to virial inflection, demyelination caused by acquired metabolic 
derangements, hypoxic–ischaemic form and demyelination caused by focal compression are 
the principal categories (Table 1 below). 3 
 
 
 
INFLAMMATORY DEMYELINATION 
Multiple sclerosis (MS) 
Classical MS 
Acute (Marburg-type) MS 
Neuromyelitis optica (Devic’s disease) 
Concentric sclerosis (Baló’s sclerosis) 
Acute-disseminated encephalomyelitis (ADEM) 
Acute haemorrhagic leucoencephalitis (AHL) 
VIRIAL DEMYELINATION Progressive multifocal leucoencephalopathy (PML) 
Other virial demyelinating diseases involved in HIV 
infection 
ACQUIRED METABOLIC DEMYELINATION Central pontin myelinolysis (CPM) 
Extrapontin myelinolysis (EPM) 
HYPOXIC- ISCHAEMIC DEMYELINATION 
COMPRESSION- INDUCED DEMYELINATION 
Table 1. Classification of CNS demyelination (according to Love 4) 
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1.1.2 Pathogenesis of the ischemic demyelination 
The ischemic demyelinating disorder, also known as age-related white matter lesion of 
the brain, is a common clinical phenomenon. It is the most frequently seen lesion in 
neuroimaging scans. 3 Ischemic demyelinization is called Leukoaraiosis (LA) in 
neuroimaging terms. Here, LA refers to diffuse areas of hyperintensity in T2-weighed 
magnetic resonance imaging (MRI) scans and it involves white matter. 5 6 One quarter of 
people over the age of 65 are affected to some degree by white matter changes. 7 Moreover, 
LA is definitely associated with cognitive decline, slowness of mental processing (dementia) 
and a poor quality of life. 8 It is a slowly developing illness, associated with various clinical 
risk factors and endogenous genetic factors. 9 Two major mechanisms have been proposed for 
it. The first is the chronic endothelial dysfunction. The increased levels of circulating markers 
of endothelial cell activation or dysfunction such as ICAM-1 and thrombomodulin were found 
in leukoaraiosis 10, and ICAM-1 levels correlated with the progression of LA. 11 The second is 
the elevated blood–brain barrier permeability, which results in the leakage of plasma 
components into the vessel wall and surrounding brain parenchyma. 12 Another hypothesis 
states that cerebral hypoperfusion may cause an energy deficit in the glia cells and neurons. 
Chronic hypoxia may be presumed to primarily damage the function of the mitochondria. 9 
Aging, hypertension, diabetes mellitus, a prior stroke event, and cardiac diseases are 
the main vascular risk factors for LA. 5 9 The temporal and occipital border zones are the most 
frequent regions of LA, because the superficial and deep perforans are end arterioles. The two 
systems do not connect, but only meet in a junctional zone around the lateral ventricles 13 14. 
The key genetic factors of LA pathogenesis are the methylene tetrahydrofolate 
reductase (MTHFR) C677T variant, the angiotensin-converting enzyme (ACE) I/D and the 
apolipoprotein E (APOE) 2 or 4 polymorphisms. 15 16 The homozygous MTHFR 677TT 
variant is associated with an eleveted serum homocysteine level, which has an unfavourable 
effect on vasoregulation. 17 18 The increased plasma homocysteine level will result in 
endothelial dysfunction. 19 Homocysteine directly damages the vascular matrix because it 
affects the biosynthetic and biochemical functions of the vascular cell. Endothelial-derived 
nitric oxide production is also caused by homocysteine. 20 LA is positively correlated with the 
plasma homocysteine level, so it is inversely correlated with the plasma folate level. 19 The 
MTHFR A1298C polymorphism is also a common genetic variant and it is thought to be a 
vascular risk factor. 21 The ACE I/D polymorphism is an important genetic factor in the renin-
angiotensin system, and it has regulatory roles in the cardiovascular system. Alongside this, 
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the homozygous ACE D/D polymorphism has an unfavourable effect on the vasoregulatory 
system. 22 Also, the incidence of the ACE D/D genotype might adversely affect 
vasoconstriction, vascular walls undermine thickening, reducing the proliferation of smooth 
muscle cells and cause a stroke. 16 The APOE 2 or 4 allele is also shown to give the rise to 
LA. 23 The APOE 4 allele leads to a reduced neuroregeneration ability, and the cytoskeleton 
can become unstable and the glia cells may become more vulnerable. 24 Despite this, the 
APOE 4 genotype is supposed to be a risk factor for ischemic brain injury or stroke. 25 In the 
presence of the APOE 2 allele, the cytoskeleton might become too rigid and this may be 
harmful during the prolonged hypoperfusion of the brain 9, and it may decrease the range of 
mechanical and chemical flexibility of the glial cytoskeleton. 9 The homozygous MTHFR 
677TT mutation in combination with the homozygous ACE D/D genotype has been 
associated with a higher risk of LA. 15  Furthermore, the MTHFR 677TT variant and the ACE 
D/D polymorphism contribute to small-vessel disease or vasoregulation impairment. These 
two genotypes in combination with the APOE 4 or 2 allele have also been reported to give 
rise to LA. 23 A new finding is the role of the aquaporin-4 (AQP-4) genotypes in LA. 26 AQP-
4 is the major water channel in the brain and the spinal cord 27, and it aids the movement of 
water between the blood and brain, and between the brain and the cerebrospinal fluid. 28 AQP-
4 is alleged to be involved in the etiology of neuromyelitis optica 29, cerebral oedema 30, 
sudden infant death syndrome 31 and migraine 32. The CT/TT genotypes of the AQP-4 
rs2075575 polymorphism could be associated with cerebral small-vessel disease and these 
genotypes may be a significant promoting factor for LA. 26 
The CADASIL study, which investigated the cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy, is caused by mutations in the 
notch-3 gene. The deposition of the extracellular portion of notch 3 in the arterial wall of both 
cerebral and systemic arteries may be identified adjacent to granular osmiophilic material, a 
deposition of unknown composition. 33 This should be investigated further. 
1.1.3 The pathogenesis of the Multiple sclerosis (MS) 
MS is a chronic immune-mediated inflammatory disease of the central nervous system 
(CNS) that typically commences in the third or fourth decade of life. Demyelination and 
subsequent axonal damage is characteristic in MS. 34 35 The main pathological symptoms of 
the disease are the destruction of the myelin sheets of nerve fibres, the relative sparsity of the 
axons, and the infiltration of inflammatory cells in a perivascular surrounding. 36 37 The 
prevalence of MS in different regions of the world ranges from 15/100,000 to 250/100,000. 38 
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In 1996, the US National Multiple Sclerosis Society (NMSS) Advisory Committee provided 
standardized definitions for MS clinical courses; namely relapsing-remitting (RR), secondary 
progressive (SP), primary progressive (PP) and progressive relapsing (PR). 39 In 2013, the 
clinically isolated syndrome (CIS) form was added and the PR form has been eliminated by 
the Committee (see figures 2 and 3 below). 40 
 
Figure 2. Relapsing-remitting MS (Lublin, 2013) 40 
CIS is a well-defined syndrome that includes optic neuritis, cerebellar dysfunction and partial 
myelitis, and it forms a part of the RR MS spectrum. 40 
 
Figure 3. Progressive MS (Lublin, 2013) 40 
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The original diagnostic criteria for MS were based on clinical features suggestive of CNS 
demyelination. However, there are other different criteria used for the diagnosis of MS as 
well. The oldest is the Schumacker committee criteria (1965) and the most recent is the 
modified McDonald criteria (2010) (Figure 4 below). 34 
 
Figure 4. Various diagnostic criteria for MS (Karussis, 2013) 34 
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The Expanded Disability Status Scale (EDSS) is a method for quantifying disability in MS 
patients (0.0: Normal neurological status and 10.0: Death due to MS). EDSS steps 1.0 to 4.5 
refer to patients with MS who are fully ambulatory, while EDSS steps 5.0 to 9.5 are defined 
in the terms of ambulation impairment. 41 
The pathogenesis in MS is not clear. It is a multifactorial disease, where 
environmental, genetic and infectious factors play important roles in its pathogenesis. 34 The 
inflammatory process is anticipated in MS pathogenesis, which is propagated by an 
autoimmune cascade. Four types of immunpathological mechanisms have been identified in 
MS lesions. Type I is T-cell mediated. In this way, demyelination is induced by macrophages 
either directly or by macrophage toxins. The most common pathology of MS lesions is type 
II, where demyelination is caused by specific antibodies and intense activity of the 
complement system. Type III is known as distal oligodendropathy, where degenerative 
changes occur in distal processes and they are followed by apoptosis. Type IV involves 
primary oligodendrocyte damage followed by secondary demyelination. 42 
The geographical situation (high risk in northern Europe, in northern US, Canada, in 
southern Australia and in New-Zealand) 43, vitamin D deficiency, smoking habits and 
infections (Epstein-Barr virus) are the most important environmental risk factors in MS. 44 
There are many genetic polymorphisms that can influence the pathogenesis of MS. 
The cytokines and their receptor genes (IL-1β, IL-2, IL-10, TNF-α, -β), chemokines and their 
receptor genes (CCL-5, -3, -4), the cytotoxic T lymphocyte associated-4 (CTLA-4) gene, 
APOE, genes associated with apoptosis, MHC classes I and II genes (HLA-DRB1* 1501-
DQA1* 0102-DQB1* 0602 (DR15)) and the T-cell receptor (TCR) gene polymorphisms are 
the most serious, and these things were described in genome-wide association studies 
(GWAS). 44 45 Viral infections (such as the Epstein-Barr virus and human herpes virus 6) are 
suspected of being a trigger for MS. 46 
1.2 Alzheimer’s disease  
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and it is the 
leading cause of cognitive and behavioural impairment in our society. AD is pathologically 
characterised by the observed accumulation and deposition of amyloid β (A β) peptides and 
the appearance of neuronal inclusion of abnormally phosphorylated tau in the brain, especially 
in the hippocampus and cerebral cortex. 47 Gene mutations in early onset familial AD (eFAD) 
may cause the production of the longer Aβ42 variant that preferentially accumulates in 
plaques. In sporadic or late-onset AD (LOAD), this commences after the age of 65 years. 
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Many genetical and environmental factors may contribute to the pathogenesis of LOAD, and 
it affects about 95 % of sufferers. Several genes are implicated as a risk factor, but it is at 
present not known how they alter amyloid levels. 48 Five percent of elderly persons over 65 
years suffer from AD and this percentage for those over 85 years increases to 30 %. By 2040, 
it is expected that 81 million people will suffer from AD. 49 
AD is multifactorial and heterogeneous disorder (Iqbal & Iqbal), and recent studies 
indicate that some epigenetic or environmental effects are risk factors to AD. 50 It has also 
been postulated that bacterial or viral infection in the brain may play an initiating role in 
amyloid plaque formation and the development of AD. 51 Various animal studies have 
demonstrated that several pathogens like Chlamydia pneumoniae, Herpes simplex, 
Escherichia coli, and Cryptococcus neoformans play a significant role in the development of 
amyloid plaque formation, and bacterial or viral CNS pathogens may speed up the 
development of AD. 52 Amyloidogenesis and most of the changes seen in AD, such as 
inflammation, brain cell atrophy, immunological aberrations, altered gene expression and 
cognitive deficits are also known to be a result of microbial infection. 53 
New scientific evidence appears to strengthen the view that the initiating event in AD 
is related to the abnormal processing of the beta-amyloid (A) peptide, ultimately leading to 
the formation of A  plaques in the brain. 51 However, the cause of the amyloid -  (A) 
imbalance is still an open question in the pathogenesis of AD.  
1.3 Genetic polymorphisms 
1.3.1 Single nucleotide polymorphisms  
Single nucleotide polymorphisms (SNPs) are single base pair positions in genomic 
DNA. By definition, the allele frequency of SNP variants is less than 1 %. SNPs could be bi-, 
tri-, or tetra-allelic polymorphisms. 54 The frequency of single base differences in two 
equivalent chromosomes is 1/1000 basis pair (bp). 55 56 57  The rate of nucleotide difference 
between two randomly chosen chromosomes is an index called nucleotide diversity. 58 Here, 
1/1000 bp means that there is on average a 0.1% chance of any base being heterozygous in an 
individual. 54 SNPs may also occur on coding and non-coding regions of the genome. 54 In the 
coding regions of the genes, they play an important role of the known recessively or 
dominantly inherited monogenic disorders. SNPs in the regulatory regions of genes might 
influence the risk of common disease, such as the apolipoprotein E and the factor V Leiden 
mutations. 59 60 Most SNPs are located in non-coding regions and these have an unknown 
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effect on the phenotype of an individual. These kinds of SNPs are routinely applied in 
population and evolutionary studies. 61 62 
1.3.2 Copy number polymorphisms 
Copy number polymorphisms (CNPs) or copy number variations (CNVs) are defined 
as a DNA segment which is 1 kb or larger and they are present with a variable copy number 
relative to a reference genome. 63 CNPs may be simple in structure, such as tandem 
duplication, and they may contain complex benefits or losses of homologous sequences at 
multiple sites in the genome. 64 CNPs influence gene expression, phenotypic variation and 
adaptation. 65 66  CNPs may cause diseases such as microdeletion and microduplication 
disorders 67 68 and increase the risk of contracting complex diseases. 69 
1.4 Associated polymorphisms with leukoaraiosis and MS 
1.4.1 Leukoaraiosis and MTHFR A1298C variant 
The methylene tetrahydrofolate reductase (MTHFR) enzyme is essential for DNS 
synthesis and methylation. Gene polymorphisms of the enzyme increase the risk for birth 
defects, different types of cancers and neurological diseases. 70 MTHFR is a regulatory 
enzyme in folate metabolism and catalyses the conversion of 5,10-methyltetrahydrofolate to 
5- methyltetrahydrofolate. 71 The MTHFR gene is located at 1p36.3. 72 The MTHFR gene has 
two SNPs (C677T and A1298C), which are associated with reduced enzyme activity and arise 
from an elevated plasma homocysteine level. Hyperhomocysteinemia is a key vascular risk 
factor as well. 71  
The principal genetic factors of LA pathogenesis are the methylene tetrahydrofolate 
reductase (MTHFR) C677T variant, the angiotensin-converting enzyme (ACE) I/D and the 
apolipoprotein E (APOE) 2 or 4 polymorhisms. 15 16 The MTHFR C677T polymorphism in 
combination with the ACE D allele is associated with a higher risk for LA. 15 MTHFR 
A1298C has been postulated as a vascular risk factor, and it can increase the risk of 
predisposition to LA or modify the development of LA. 21  
1.4.2 Leukoaraiosis and mitochondria 
Chronic hypoperfusion seems to play a crucial role in the development of vascular 
demyelinisation. The neurons and the glia cells have an energy deficit due to the ischemia. 
The function of the mitochondria (MIT) may be damaged during the chronic hypoperfusion 
period by the intracellular electrochemical changes (changes in the normal polarisation of the 
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glia cells and neurons, reversions in the intracellular pH and cation concentrations). The 
damaged MIT is unable to carry out the well-organized production of energy for the cytosol. 
Despite this, mutations of the mitochondrial DNA or tRNA trigger a quality malfunction in 
the affected mitochondria. The absolute number of mitochondria is in all likelihood essential 
for the neuron and glia cells. 73 In clinical studies, direct data cannot be readily obtained. 
However, the number of mitochondria in other tissues, which are functionally continually 
connected with brain tissue, may be informative. The white blood cells, for example, circulate 
and communicate with the brain tissue all the time. Their energetic storage may be important 
for the maintenance of the brain, since they act as a scavenger of the free radicals; and they 
also undermine the integrity of the neurovascular system of the brain. The white blood cells, 
vascular cells and brain tissue all most likely act in unison. However, there is almost no data 
regarding the segregation of the number of mitochondria among the different cell types. The 
absolute number of mitochondria in the white blood cells may provide an indication of the 
absolute number of mitochondria in the given individual.  
With this in mind, we examined whether the number of mitochondria in the white 
blood cells are associated with the development of LA.  Besides genetic heterogeneity of the 
mitochondrial DNA, there exist two big types of mitochondrial DNA; namely one with D-
loop sequences and one without them. The former is called mitochondrial DNA (mDNA), 
while the latter is actually a mitochondrial DNA with a large and common deletion of 123-
1256 bp (dmDNA). This deleted mitochondrial DNA appears to malfunction in some 
unknown way. 
1.4.3 Multiple sclerosis and human beta defensins 
Defensins are the largest family of antimicrobial peptides (AMPs). Defensins and 
defensin-like proteins are quasi universal participants in host defence against infection. 74 
Defensins are small cysteine-rich peptides that can be classified as either α-defensin or β-
defensin, depending upon the arrangement of six critical cysteine residues. 75 Defensins work 
actively against Gram-positive and –negative bacteria, viruses (adenovirus, herpes virus, 
influenza virus, cytomegalovirus, HIV and fungi. 76 The most frequently studied antimicrobal 
peptides are the human β-defensins (hBDs). 77 The ß-defensins comprise the largest group, 
with around 40 members encoded in the human genome. 78 The majority of studies to date 
have focused on HBD1 and HBD2. Human β-defensins are produced by epithelial cells of the 
skin, gut, respiratory and urogenital tissue. HBD1 is also expressed by leukocytes. HBD1 has 
been observed in human astrocytes and microglia cells. 79 Furthermore, epithelial cells, the 
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expression of HBD2, has been detected in human monocytes, macrophages, and dendritic 
cells. 80 Astrocytes may provide alternative ways of local HBD2 synthesis in the brain. 79 The 
generally synthesized defensins as AMPs may protect the brain against bacterial or virial 
infections and defensins, and have immunomodulatory functions. 
Defensin genes have been mapped to 8p22-p23. 81 In this case, two types of genetic 
polymorphisms have been identified in genes encoding defensins, copy number 
polymorphisms (HBD2 encoded by the gene DEFB4) and single nucleotide poymorphisms 
(HBD1 encoded by the gene DEFB1). Three frequent SNPs at positions G-20A (rs11362), C-
44G (rs 1800972) and G-52A (rs1799946) in the 5’-untranslated region (UTR) of DEFB1 
have been described. 82 83 
The β-defensins are found to be impaired in many inflammatory diseases, including 
Crohn's disease, psoriasis, pulmonary inflammation 84 85, and periodontal disease. 86 β-
defensins have been hypothesised to play a role in the etiology of neurodegeneration with a 
focus on traumatic brain injury, which is a risk factor for AD. 87 The role of HBDs genes as 
potential modifiers in MS had not been hypothesised previously. 
1.4.4 Alzheimer’s disease and human α- and β- defensins 
New findings strengthen the hypothesis that the initiating event in Alzheimer's disease 
(AD) is related to the abnormal processing of the beta-amyloid (A ) peptide, ultimately 
leading to the formation of A  plaques in the brain. 47 However, the precise cause of the 
amyloid -  (A )  imbalance is still an unresolved question in the pathogenesis of AD. 
Recently, a hypothesis was put forward that brain infections with bacteria or viruses may play 
an initiating role in amyloid plaque formation and the development of AD. 48 This had led 
some scientists to take more seriously the potential contribution of pathogenic microbes to 
ageing and AD. In particular, most of the changes observed in AD, such as inflammation, 
brain cell atrophy, immunological aberrations, amyloidogenesis, altered gene expression and 
cognitive deficits are also viewed as a consequence of microbial infection. The inflammatory 
response to an infection may indirectly lead to an upregulation of amyloid production, thereby 
initiating the amyloid cascade. 49 It is suspected that neuropathological alterations might be 
associated with abnormal expression and the regulatory function of antimicrobial peptides 
(AMPs), including defensins. 50 51 It is worth mentioning that AMPs in general are able to 
cross the blood-brain barrier (BBB). Apart from their natural antimicrobial effects, AMPs also 
trigger immunostimulatory effects, including the upregulation of TNF-, IL-8, and 
chemoattraction. An overproduction of defensins as AMPS might be a consequence of 
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previous infections, or even the alteration of the microbiome. This is why we hypothesise that, 
based on existing literature, 49 an upregulation of the production of defensins as AMPs might 
trigger the aggregation of amyloid in the brain. Human β-defensins have been hypothesised to 
play a role in the aetiology of neurodegeneration with a focus on chronic inflammation-
associated brain injury, which is a risk factor for AD. 52 
Human α-defensins include human neutrophil peptide 1-4 (HNP1-4) and intestinal 
human defensins (HD-5 and HD-6) produced by Paneth cells. Besides the antimicrobial 
effects, alpha defensins display chemotactic activity and induce proinflammatory cytokines. 88 
89 90 Neutrophil granulocytes are considered to be the main cellular origin of α-defensins here; 
and HNP 1-3 comprise 30%-50% of the granule proteins. HNPs may be released into the 
extracellular milieu following granulocyte activation as a consequence of degranulation, 
leakage, cell death, and lysis during inflammation. 53 
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2. AIMS OF THE STUDY 
 
An investigation of various genetic polymorphisms in leukoaraiosis and multiple sclerosis, 
which have a multifactorial origins. 
This is involved examining: 
 
 The methylene tetrahydrofolate reductase (MTHFR) A1298C genetic variant in 
patients with leukoaraiosis; 
 
 The absolute number of mitochondria in patients with leukoaraiosis; 
 
 The role of human beta-defensisns-1 and -2 (HBD1, HBD2) in MS: the relevance of 
the SNPs of the DEFB1 gene and the copy number polymorphism of the DEFB4 
genes in multiple sclerosis. 
 
 The role of defensin β-2 and α defensins (HNP 1-3) in Alzheimer’s disease. 
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3. MATERIALS AND METHODS 
3.1 Patients and controls 
Control subjects and patients gave their informed consent to their participation in our 
studies and the local ethics committees (Human Investigation Review Board of Pándy 
Kálmán County Hospital in Gyula, Hungary, Human Investigation Review Board at the 
University of Szeged) approved it. All controls and patients were of Hungarian ethic origin 
and resident in Hungary. 
3.1.1 MTHFR A1298C variant and the absolute number of mitochondria in the patient group 
with leukoaraiosis and controls 
Leukoaraiosis was defined by Fazekas et al. as irregular periventricular 
hyperintensities extending into the deep white matter in T2 weighted MRI scans (grade 3) and 
deep white matter hyperintense signals with initial indications of confluence of the foci or 
with large confluent areas in the T2 weighted MRI scans (grade 2-3). 91 
The MTHFR A1298C study population comprised 198 LA patients with a mean age of 
64.9 ± 9.23 years (105 women and 93 men). The patients were diagnosed and recruited from 
the Department of Neurology of the Pándy Kálmán County Hospital in Gyula. In contrast, the 
controls consisted of 235 neuroimaging alteration free subjects (127 women and 108 men, age 
54.7 ± 12.8 years). They were randomly selected from the Pándy Kálmán County Hospital 
practice register subject to the proviso of having negative brain MRI scans. The clinical risk 
factors were registered in Table 2.  
Clinical features LA group (n= 198) Control group (n=235) 
Sex (females/males) 105/93 127/108 
Age (years) 64.9±9.23 54.7±12.8 
BMI (kg/m2) 24.3±2.3 24.6±1.98 
Cholesterol (mM) 5.41±1.32 5.12±1.34 
Triglycerides (mM) 1.45±1.59 1.38±0.96 
Hypertension 69.7 % 18.7 % 
Diabetes mellitus 15.2 % 13.2 % 
Smokers 15.2 % 11.9 % 
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Drinkers 6.1 % 4.3 % 
Ishaemic heart disease 10.1 % 6% 
Table 2. Clinical and laboratory data on patients and control subjects 
The mitochondria study group consisted of 234 LA patients (123 women and 111 men, 
age 71.6 ± 10.8 years) and 123 MRI alteration – free controls (65 women and 58 men, age 
59.4 ± 8.62 years). Once again, the patients and controls were recruited from the Pándy 
Kálmán County Hospital in Gyula, Hungary. The relevant clinical data is listed in Table 3 
below. 
Clinical features LA group (n= 234) Control group (n=123) 
Sex (females/males) 123/111 65/58 
Age (years) 71.6±10.8 59.4±8.62 
BMI (kg/m2) 24.6±2.33 24.4±3.42 
Cholesterol (mM) 5.91±1.24 5.52±1.56 
Triglycerides (mM) 1.48±0.91 1.50±0.82 
Hypertension 46.6 % 22.0 % 
Diabetes mellitus 17.9 % 4.88 % 
Smokers 29.9 % 28.5 % 
Drinkers 12.0 % 9.0 % 
Table 3. Characteristics of patients and control subjects 
3.1.2 Human beta defensins in patients group with multiple sclerosis and controls 
The study included 250 MS patients. The population in question contained 250 RR 
(relapsing remitting) and 53 SP (secondary progressive) persons with a mean age of 44.23 ± 
13.02 years. Patients were diagnosed and registered at the Department of Neurology at the 
University of Szeged and Department of Neurology of the Pándy Kálmán County Hospital in 
Gyula. Here, the criterion was applied in the diagnosis of clinically definitive MS. 92 The RR 
type was described as the presence of exacerbations followed by complete or partial 
remissions. The SP form was defined as the presence of a gradual onset of the disability 
lasting six months or more, with or without relapses, in subjects who - before the progressive 
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phase - had exhibited an RR course. 34 The clinical classification was also supported by the 
MRI criteria. 93 41 MRI protocols were established in accordance with the European Concerted 
Action Guidelines. 41 The expanded disability status scale score (EDSS) for the study 
population ranged from 0 to 8 (mean, 3.37 ± 1.94) with a disorder duration of less than 1-20 
years (mean, 8.83 ± 2.16 years). All patients gave their informed consent to participate in the 
study, and the local ethics commitees – Human Investigation Review Board at the University 
of Szeged Albert Szent-Györgyi Medical and Pharmaceutical Center and the Human 
Investigation Review Board of Pándy Kálmán County Hospital in Gyula – gave prior 
approval to the study. The control patients comprised 232 age and gender-matched healthy 
blood donors, while the control group was selected from blood donors at the Regional Center 
of the Hungarian National Blood Transfusion Service in Szeged, Hungary. Statistical data 
concerning the MS patients and controls is given in Table 4 below. 
Clinical 
parameters 
Relapsing-
remitting MS  
(n= 197) 
Secondary 
progressive MS 
(n=53) 
Overall MS 
(n=250) 
Controls 
(n=232) 
Sex 
(males/females) 
49/1148 16/37 65/185 168/64 
Age (years, 
means, SD) 
45.7±14.5 56.75±12.68 44.23±13.02 46.8±11.98 
Disease duration 
(years, means, 
SD) 
10.36±10.02 7.3±4.7 8.83±2.16 Not relevant 
EDDS score 
(means, SD) 
2.36±1.48 5.5±1.39 3.37±1.94 Not relevant 
Table 4. Statistics for the MS patients and controls 
3.1.3 Human α- and β- defensisn in Alzheimer’s group and controls 
The study included 206 AD patients (69 men and 137 women, the average age and 
standard deviation (S.D.) was 76.42 ± 4.21 years, and the average onset was at 65 years of 
age. A clinical diagnosis of AD was established by an initial evaluation via careful history 
taking (personal and family histories), neurological and psychiatric examinations, along with 
the assessment of psychometric tests to confirm cognitive impairment. In addition, a brain CT 
scan or MRI was performed in each case, and in some cases SPECT was performed to rule 
out other possible neurological disorders. Routine laboratory processing involving the 
determination of thyroid hormone levels was also carried out. Each participants fulfilled 
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criteria outlined in the Fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV, 1994) and seemed to have AD based on the criteria of NINCDS–
ADRDA. 94 95 The cognitive evaluation of AD patients was performed using the AD 
Assessment Scale – Cognitive Subscale (ADAS-Cog) 96 77, the Mini-Mental State Exam 
(MMSE) 97 98, and the Clock Drawing Test (CDT). 99 To exclude pseudodementia caused by 
depression, a patient’s mood was scored via the Beck Depression Inventory 100,which might 
be too restrictive 101, but only patients that had fewer than 12 BDI scores were included in the 
study. The control group comprised 250 age and sex matched healthy volunteers (92 men and 
158 women, average age ± S.D. 72.69 ± 6.82 years) with normal cognition (MMSE score 
higher than 28) recruited from the Regional Center of the Hungarian National Blood 
Transfusion Service and the Department of Neurology at the University of Szeged (2010 
January - December 2014).  
All the cases and controls were of Hungarian ethnic origin. Informed consent was 
obtained from all the patients or responsible guardian in the case of incapacity and controls. 
When conducting our experiments with the patients, we followed the guidelines of the Patient 
Right’s Protection Act of our institutions and international laws. 
The local Ethics Committee of the Hungarian Investigation Review Board also gave prior 
approval of the study.  
3.2 Genotyping procedures 
3.2.1 DNA isolation 
Genomic DNA was extracted from 200 µl of peripheral whole blood anticoagulated 
with EDTA. Here, two kinds of leukocyte DNA extraction were applied. One type of DNA 
isolation was the desalting method devised by Miller et al. 102 The other method was DNA 
extraction with the High Pure PCR Template Preparation Kit (Roche Diagnostic GmbH, 
Mannheim, Germany, Cat.No: 1796828) and the manufacturer’s instructions were adhered to. 
The DNA concentration was measured with a Qubit fluorometer (Invitrogen, Carlsbad, USA). 
Afterwards, the genomic DNA was then stored at -20 oC until needed. 
3.2.2 Determination of MTHFR A1298C variant in leukoaraiosis 
The genetic variants of MTHFR A677T and A1298C were identified by using a 
LightCycler probe system. 21 The amplification mix contained the following ingredients: 1 µl 
of sample DNA, 1 µl buffer (Light Cycler DNA Master Hybridization Probes 10X Buffer, 
Roche), 3 mmol/l MgCl, 2% dimethyl-sulphoxide, primers and probes listed in Table 5, with 
23 
 
a total volume of 10 µl per single tube reaction. The assay conditions were 90 sec at 94 oC, 
and 40 cycles of 94 oC for 10 sec, and 50 oC for 10 sec and the elongation (72 oC for 10 sec). 
The next step was a melting point analysis in the F2 channel (640 nm) of the MTHFR A677T 
variant. The melting point of the A677T mutant allele was 67 oC and the wild type was 69 oC 
(Figure 5). The A1298C polymorphism was measured in the F3 channel at 705 nm. Here, the 
melting points of the wild type and the mutant allele were 54 oC and 58 oC, respectively 
(Figure 6). 
Name Sequence Notation Concentration 
(µmol/l) 
MTHFR C677T mutation 87 
MTHFR-for TgA Agg AgA Agg TgT 
C XT gCg ggA 
X=LC-Red640 0.1 
MTHFR-rev Agg Acg gTg Cgg TgA 
gAg Tg 
- 0.5 
MTHFR-probe AgC AgC gTg ATg ATg 
AAA TCg gCT CC-
Fluorescein 
3’Fluorescein 0.2 
MTHFR A1298C mutation 
MTHFR2-for 88 CTT Tgg ggA gCT gAA 
ggA CTA CTA C 
- 0.1 
MTHFR2-rev 88 CAC TTT gTg ACC 
ATT CCg gTT Tg 
- 0.1 
MTHFR2-probe 21 CTT TCT TCA CTg 
gTC AgC-Fluorescein 
3’Fluorescein 0.1 
MTHFR2-anchor 21 LCRed705-CCT CCC 
CCC ACA TCT TCA 
gC-Phosphate 
5’LCRed705 
3’Phosphate 
0.1 
Table 5. Primers and probes of the MTHFR C677T and A1298C mutations  
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Figure 5. Examination of MTHFR C677T variants. The dotted line represents CC677, the 
continuous line represents C677T, and the dashed line represents 677TT. 
 
 
 
Figure 6. Examination of MTHFR A1298C variants. The dotted line represents AA1298, the 
continuous line represents A1298C, and the dashed line represents 1298CC. 
3.2.3 Determination of the absolute number of mitochondria per cell in leukocyte cells 
The TaqMan real-time PCR assay, specially designed for the amplification of 
mitochondrial (m) and deleted mitochondrial (dm) DNA, was carried out using a specific set 
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of primers and probes (mDNA forward 5’-ATG GCC AAC CTC CTA CTC CTC ATT-3’; 
reverse 5’-TTA TGG CGT CAG CGA AGG GTT GTA-3’ and a HEX-labeled probe 5’-
[HEX]CGC AAT GGC ATT CCT AAT GCT TAC CG[TAM]; dmDNA forward 5’-ACA 
CAA ACT ACC ACC TTT GGC AGC-3’; reverse 5’-TTC GAG TGC TAT AGG CGC TTG 
TCA-3’ and a FAM-labeled probe 5’-[6FAM]ACG AGG AAT ACC TTT CCT CAC AGG 
TTT CT[TAM]). Quantitative mt and dmt DNA amplification data were normalised to 
GAPDH [ROX-labelled GAPDH (Sigma-Aldrich®)] as an internal reference gene, which was 
coamplified simultaneously in a single-tube assay. The primers and probes were all obtained 
from Sigma-Aldrich®. Thermal cycling was performed on a Bio-Rad CFX96TM Real-Time 
PCR system. Here, amplification reactions (10 µl each) were performed in duplicate with 1 µl 
of template DNA. The amplification mix contained the following ingredients: 5 µl of iQTM 
Multiplex Powermix (Bio-Rad, USA), 0.4 µl of each primer, 0.1 µl of each fluorogenic probe, 
1.3 µl of RNase and DNase-free water (Fermentas, Vilnius, Lithuania), and 1 µl of sample 
DNA, in a total volume of 10 µl per single tube reaction. The assay conditions were 3 min at 
95 oC, and 44 cycles of 95 oC for 10 sec and 60 oC for 45 sec. The quantification was 
evaluated using the comparative CT (Threshold Cycle) method. 103 
3.2.4 Determination of the DEFB1 SNPs in multiple sclerosis 
Human β-defensin 1 (DEFB1) – Genotyping was carried out using Custom TaqMan® 
SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA). Fluorogenic minor 
groove binder probes were utilised for each case using the dyes-6-carboxy-fluorescein FAM 
(excitation 494 nm) and VIC (excitation 538 nm): DEFB1 polymorphisms: c.-20G > A 
(rs11362) Applied Biosystems code c_11636793_20, DEFB1 c.-44C > G (rs1800972) 
c_11636794_10, and DEFB1 c.—52G>A (rs1799946) c_11636795_20. Thermal cycling was 
performed on a Bio Rad CFX96TM Real-Time PCR system. The amplification mix contained 
the following ingredients: 6 µl of Maxima® Probe/ROX qPCR Master Mix (Fermentas, 
Vilnius, Lithuania), 0.3 µl of primer-probe mix, 5.1 µl of RNase and DNase-free water 
(Fermentas, Vilnius, Lithuania), and 1 µl of sample DNA, in a total volume of 11.4 µl per 
single tube reaction. The assay conditions were 10 min at 95 oC, and 40 cycles of 95 oC for 15 
s and 60 oC for 1 min. Each 96-well plate contained 93 samples of an unknown genotype and 
three reactions with reagents, but no DNA. DNase-free water was used as the non-template 
control. The initial and post assay analyses were performed using the Bio Rad CFX96TM Real-
Time system Precision Melt AnalysisTM software package. 
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3.2.5 Determination of the DEFB4 gene copy number in multiple sclerosis 
The determination of the DEFB4 Gene Copy Number – A TaqMan real-time PCR 
assay, specifically employed for the amplification of genomic DEFB4, was performed using a 
specific set of amplification primers (forward 5’-TGAAGCTCCCAGCCATCAG-3’; reverse 
5’-TATTTCCCTGGCCCATCTCA-3’ and a VIC-labelled probe 5’- VIC- 
ATCTCCTCTTCTCGTTCC-MGB). Quantitative DEFB4 amplification values were 
normalised to ABL [FAM-labelled albumin (Applied Biosystems, Cat. No. 4331182)] as an 
internal reference gene, which was added to each single tube. The primers and probe of 
DEFB4 were designed using Primer Express 3.0 (Applied Biosystems). The probes were 
purchased from Applied Biosystems, while the primers were obtained from Invitrogen 
(Carlsbad, CA, USA). Real-time PCR was carried out using the Bio Rad CFX96TM Real-
Time PCR system. The amplifications were performed in triplicate with the Maxima® Probe 
/ROX qPCR Master Mix (Fermentas, Vilnius, Lithuania), 20 ng of template DNA, 300 nM 
per primer and 200 nM of each fluorogenic probe. The steps of thermal cycling were 10 min 
at 95 oC, and 40 cycles of 95 oC for 15 s and 60 oC for 1 min. The quantification was 
evaluated using the comparative CT (Threshold Cycle) method. 103  
3.2.6 The determination of the DEFB4 gene copy number in AD patients 
A TaqMan real-time PCR assay, specially designed for the amplification of genomic 
DEFB4, was performed as described previously. 104 Put briefly, quantitative DEFB4 
amplification data was normalised to ABL [FAM-labelled albumin (Applied Biosystems, Cat. 
No. 4331182)] as a standard reference gene that is actually present only in 2 copies in the 
genome. The reference gene was used as an internal standard 105 and added to every single 
tube. Once again, the quantification was evaluated by applying the comparative CT 
(Threshold Cycle) method. 103 
3.3 ELISA procedures 
3.3.1 Plasma levels of HBD2 with Capture ELISA in multiple sclerosis 
ELISA of hBD2 (Alpha Diagnostic San Antonio, TX, USA) was used to test for the 
occurrence of the human β-defensin 2 peptide in the plasma of controls and patients, based on 
the manufacturer’s recommendations. Here, the detection limit of the hBD2 ELISA Kit was 
0.8 pg hBD2 protein/ml. 
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3.3.2 Human cerebrospinal fluid (CF) collection for defensin ELISA in AD 
The CF samples used in this study were derived from patients undergoing a lumbar 
puncture in the L4–L5 vertebral interspace. All the procedures were conducted in the morning 
and all the samples (12 mL) of CF taken from each patient and control subjects were collected 
into polypropylene tubes. These samples were then transferred to the laboratory at -20 °C 
within 1-2 hours, and each CSF sample was divided into aliquot and frozen to minimise any 
metabolic damage. A routine laboratory investigation was performed and the remainder of the 
samples were stored at -80 °C until needed.  
Ethical permission for lumbar puncture was also obtained from the Ethics Committee 
of the University of Szeged, Hungary, where written informed consent was required for all 
probands (permit no. 184/2012). 
3.3.3 ELISA of human β-defensin 2 (hBD2) in AD 
ELISA of hBD2 (Alpha Diagnostic San Antonio, TX, USA) was used to test for the 
occurrence of the human β-defensin 2 peptide in the sera and in the CF of controls and 
patients, based on the manufacturer’s recommendations. Here, the detection limit of the hBD2 
ELISA Kit was 0.8 pg hBD2 protein/ml. 
3.3.4 An assay of the HNP 1-3 concentrations in AD 
The HNP1-3 concentrations in sera and in the CF were determined by ELISA (Hycult-
Biotech HK324, Uden, The Netherlands) based on the recommendations of the manufacturer. 
3.4 Statistical analysis 
3.4.1 A statistical analysis of the MTHFR A1298C variant in leukoaraiosis 
The clinical data was expressed as means ± SD, where appropriate. The differences 
between the clinical parameters in the stroke group and the controls were assessed via the χ2-
test or the Mann–Whitney test, where appropriate. As a first step, we analysed whether the 
MTHFR A1298C variant was a risk factor for LA. Since MTHFR C677T was not found to be 
an independent risk factor for LA in our earlier study, an analysis of the distribution of the 
C677T variant was not our primary goal. However, as a second step, we investigated whether 
the presence of the C677T variant had a modifying effect if it occurred in combination with 
the MTHFR A1298C variant. The frequencies of the genetic variants were then compared 
with the χ2-test. After performing a univariate statistical analysis, we carried out logistic 
regression calculations in order to discover differences between the LA subjects and the 
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controls. Logistic regression analyses were performed using the statistical package SYSTAT 
10 (Chicago, USA) for Windows. 
3.4.2 A statistical analysis of absolute mitochondrial number in laukoaraiosis 
The number of mDNA and dmDNA per white blood cell in the LA group were 
compared with those in the control group using the two-paired T test. In order to make the 
comparison more sensitive biologically, the mathematical difference between the number of 
mDNA and mdDNA per cell was divided by the sum of the number of mDNA and dmDNA 
per cell in the same individual. This calculated ratio gave the weight of uncompensated 
dmDNA per cell, which was called the K ratio. In the equilibrium state, K= number of 
mDNA--number of dmDNA / the number of mDNA + number of dmDNA. The K values 
were compared statistically between the LA and control groups by means of the two-paired T-
test. An univariate statistical analysis was followed by a logistic regression comparison 
involving the age, hypertension, diabetes mellitus (for the LA and control groups) and K 
values.  
3.4.3 A statistical analysis of human beta defensins in multiple sclerosis 
The significance of the genotype frequency was analysed via the chi-square test and 
the Fischer test. Here, the level of significance was p < 0.05. The genotype frequencies of 
SNPs were tested for deviation from the Hardy-Weinberg equilibrium via the chi-square test, 
with one degree of freedom. Plasma levels of human β-defensin 2 were expressed as medians 
with the Mann-Whitney test. The group means were then discriminated via the ANOVA test 
and then Bonferroni’s multiple comparison tests was applied.  
The GraphPad prism 5 statistical program was utilised in all the statistical calculations 
(GraphPad Software Inc. San Diego, CA, USA). 
3.4.5 A statistical analysis of α- and β- defensins in Alzheimer’s disease 
The significance of the genotype frequency was analysed via the Mann-Whitney test. 
Here, the level of significance was p < 0.05. The levels of human β-defensin 2 and HNP 1-3 
in the sera and in the cerebrospinal fluids (CF) were expressed as mean ± SEM, and the 
significance was determined using the Student unpaired t-test. The GraphPad Prism 5 
statistical program was again used to perform all the statistical calculations (GraphPad 
Software Inc. San Diego, CA, USA).  
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4. RESULTS 
4.1 MTHFR A1298C variant in leukoaraiosis 
The presence of the 1298C variant (heterozygous A1298C or homozygous 1298CC) 
was found to be an independent risk factor for LA (54.1% vs 43.8%; adjusted OR, 1.6; 95% 
confidence interval, 1.2–2.5; p <0.034). The presence of the heterozygous T677C or A1298C 
variants did not increase the risk of contracting LA if they occurred by themselves. However, 
the clustering of both heterogeneous variants in the same person created a slight risk of LA 
(4% vs 0.4%; adjusted OR, 79.5; 95% confidence interval, 1.2–98.5; p <0.008; Table 6). Data 
concerning the combinations of the two variants are given in tables 7 and 8 below. 
Genotypes LA (n= 198) Controls 
(n=235) 
P Crude OD, 95 % 
confidence interval 
MTHFR 
A1298C + 
C677T 
8 (4%) 1 (0.4%) <0.008 79.5 (1.22-98.5) 
Table 6. Synergistic interaction between the heterozygous MTHFR A1298C and C677T 
genotypes 
Genotypes MTHFR 
1298AA 
MTHFR 
A1298C 
MTHFR 
1298CC 
MTHFR CC677 36 43 15 
MTHFR C677T 71 41 1 
MTHFR 677TT 25 1 2 
Table 7. Distribution of the different genotypes among the control subjects 
Genotypes MTHFR 
1298AA 
MTHFR 
A1298C 
MTHFR 
1298CC 
MTHFR CC677 23 32 15 
MTHFR C677T 46 49 3 
MTHFR 677TT 22 8 0 
Table 8. Distribution of the different genotypes among the LA patients 
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4.2 Absolute number of the mithoconria per cell in leukocyte cells in leukoaraiosis 
The frequency of hypertension in the LA group was higher than that in the controls. 
Interestingly, the mDNA content and dmDNA content did not differ significantly between the 
LA and control groups. After performing a logistic regression analysis, we found that the 
calculated value of K for the LA group was significantly lower than that for the controls. 
These logistic regression analyses were carried out in order to learn the differences between 
the LA and controls with regard to the age, hypertension and diabetes mellitus. In this way, 
we were able to minimise the confounding effects of these clinical factors, and their 
association with the reduced number of mitochondria (LA: K 0.37, 95% CI 0.05; controls: K 
0.48, 95% CI 0.076; p<0.001).  
Genotypes LA group (n=234) Controls (n=123) 
Number of non-deleted MIT per cell 
(means±2SD) 
5.5±0.45 5.4±0.5 
Number of deleted MIT per cell 
(means±2SD) 
3.45±0.5 3.5±0.5 
*K 0.37±0.03 0.48±0.003** 
* Non-deleted mitochondrial DNA content per cell minus deleted mitochondrial DNA content 
per cell divided by the sum of the contents of deleted and non-deleted mitochondrial DNA per 
cell [K = (mDNA — dmDNA) / (mDNA + dmDNA)] 
** p<0.001: the leukoaraiosis group was compared with the control group by means of the 
two-paired T-test. 
Table 9. Distributions of the number of deleted and non-deleted mitochondrial DNA per cell 
in the leukoaraiosis and control groups 
4.3 Human β –defensin 1 genotyping in MS 
DEFB1 c.-20G<A, DEFB1 c.-44C>G, and DEFB1 c.-52G>A polymorphisms 
The total numbers of MS patients in these genotyping experiments was 250 and the 
control group contained 200 healthy members. The prevalence of the three genotypes of 
DEFB1 and the controls subjects were found to be in accordance with the Hardy-Weinberg 
equilibrium (DEFB1 c.-20G>A p= 0.677 and in the control group p= 0.912; DEFB1 c.-
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44C>G p= 0.999 and in the controls p= 0.723; DEFB1 c-52G>A p= 0.657 and in the control 
group p= 0.253, respectively).  
The genotypic distributions of DEFB1 c.-20G<A, DEFB1 c.-44C>G, and DEFB1 c.-52G>A 
polymorphisms are listed in tables 10, 11 and 12 below.  
 GG (%) GA (%) AA (%) χ2 test* 
Patients with MS 
(n=250) 
78 (31) 131 (53) 41 (16) 0.4106 
Controls (n=200) 62 (31) 96 (48) 42 (21) 
*chi square test vs. controls 
Table 10. Distribution of DEFB1 c.-20G>A genotypes in MS patients  
 CC (%) CG (%) GG (%) χ2 test* 
Patients with MS 
(n=250) 
160 (64)++ 80 (32) 10 (4)+ 0.0002 
Controls (n=200) 90 (45) 92 (46) 18 (9) 
 
* chi square test vs. controls 
+ Fischer test: p= 0.0317; OR= 2.384; CI= 1.074-5.288 
++ Fischer test: p<0.0001; OR= 0.465; CI= 0.318-0.680 
Table 11. Distribution of DEFB1 c.-44C>G genotypes in MS patients  
 GG (%) GA (%) AA (%) χ2 test* 
Patients with MS 
(n=250) 
100 (40) 111 (44) 39 (16) 0.766 
Controls (n=200) 80 (40) 84 (42) 36 (18) 
*chi square test vs. controls 
Table 12. Distribution of DEFB1 c.-52G>A genotypes in MS patients  
 
In the genotype distribution no significant difference was found between the DEFB1 c.-
20G>A and the controls (P= 0.4106). Similarly, in the genotypes no significant differences 
were found between the DEFB1 c.-52G>A and the healthy subjects (P= 0.766). In the case of 
the DEFB1 c.-44C>G polymorphism, in the genotype distribution there was significant 
difference between the patient group and the control group (p= 0.0002; Table 11 and Figure 
7).  
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Figure 7. Distribution of DEFB1 c.-44C>G genotypes in MS patients and controls. Using the 
Fischer test, both the frequency of GG (*P= 0.0317; OR= 2.384; CI= 1.074-5.288) and the CC 
genotypes (**p<0.0001; OR= 0.465; CI= 0.318-0.680) vs. controls were found to be 
significantly different. 
4.4 Determination of the DEFB4 gene copy number in MS 
The measurement of CN was performed in 250 patients in the MS group and in 232 
healthy controls. Here, the range of copy numbers was found to be between 2 and 8 per 
genome in the control group. Of these, four copies were the median number of the healthy 
controls. The proportions of control individuals who carried the median (4), more than median 
(>4), or less than the median (<4) number of copies were 39%, 33% and 28%, respectively. 
For the patients with multiple sclerosis, the frequency distribution of the subgroups was 
different from that of the control group (p= 0.002, Figure 2). Among the patients with MS, 
43% had a lower (<4) copy number compared to that for the control subjects. The frequency 
of a CN >4 was only 27% among the patents with MS and 33% among the controls. As we 
can seen when the copy numbers were higher than 4 there was no statistical difference 
between MS patients and control subjects. However, there was a lower frequency among 
patients (27 %) than in the control subjects (33%) (see Figure 8). 
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Figure 8. Distribution of DEFB4 gene CN in MS patients and controls. Applying the Fischer 
test, the frequency of CN <4 between the MS group and the control subjects was found to be 
significantly different (*p= 0.0005; OR= 0.507; CI= 0.3464 to 0.7413). 
4.5 Plasma levels of hBD2 
Samples of patients with MS and controls with known CNs of DEFB4 were used to 
perform ELISA for hBD2 in order to determine whether the plasma levels of hBD2 varied 
relative to the CN variation of the DEFB4 gene. The levels of human β-defensin 2 in MS 
patients (n= 80) were significantly lower overall than those in the control subjects (n=50). 
Here, the median levels of hBD2 in the patients were 150.6 ± 12.71 pg/ml vs 262.1 ± 23.82 
pg/ml in the control group, with p<0.0001; Figure 9). The circulating level of human β-
defensin 2 has a close correlation with the CN in the control group. And, similar to the 
controls, the plasma levels were found to be significantly lower in the CN<4 group (135.3 ± 
25.49 pg/ml), compared to patients with copy numbers of 4 (173.7 ± 44.09 pg/ml). The 
defensin levels, however, were not elevated in patients with CN>4 (148.9 ± 31.21 pg/ml) (see 
Figure 8). 
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Figure 9. The median levels of hBD2 in the patients (**150.6 ± 12.71 pg/ml) and in the 
controls (*262.1 ± 23.82 pg/ml). The horizontal lines represent medians. Here, p < 0.0001 
based on the Mann-Whitney test. 
 
Figure 10. Plasma levels of hBD2 in MS and in control group with DEFB4 copy numbers of 
<4, 4, >4. The values are means and SDs of the results for 50 samples in the control group and 
80 samples in MS patients. The differences among group means were determined using the 
ANOVA test (difference between patients and controls with p < 0.0001) followed by 
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Bonferroni’s multiple comparison test ** CN<4 MS patients vs controls with p < 0.001, ** 
CN=4 MS patients vs controls p < 0.001, *** CN>4 MS group vs control patients p < 0.001. 
4.6 Copy number (CN) polymorphism of DEFB4 in AD 
The measurement of CN was performed in 206 patients in the AD group and in 250 
subjects in the control group. Here, the median CN in the controls was 4, the 75% percentile 
was 5, and the 25% percentile was 3.4. In the AD patients the median was 5, with a 75 % 
percentile of 6, and with a 25% percentile of 4, with p<0.001 using the Mann-Whitney test 
(see Figure 11). 
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Figure 11. CN polymorphism of DEFB4 in Alzheimer’s disease 
4.7 Serum levels of hBD2 in AD 
In a pilot study, the levels of human β-defensin 2 in the sera of 52 patients with AD 
and in 45 subjects in the control group were measured. Significantly higher levels of hBD2 
were found in AD patients than those in the control group (see Figure 12). The median levels 
were 265.5 pg/ml in AD vs. 169.4 pg/ml in controls, respectively (p < 0.01). 
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Figure 12. Serum levels of human β-defensin 2 in AD 
4.8 Levels of hBD2 in cerebrospinal fluids (CF) in AD 
Though relatively lower concentrations of human β-defensin 2 were detected in the CF 
of the study group than in their serum levels, the difference between the AD and control group 
was significant. Once again, patients with AD (n= 43) exhibited higher hBD2 concentrations 
in their CF as than those in the control subjects (n = 40); 8.6 pg/ml vs 1.201 pg/ml in the 
control group (p < 0.001; see Figure 13). 
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Figure 13. Levels in hBD2 in cerebrospinal fluids in AD 
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4.9 Serum levels of HNP1-3 (α-defensin) in AD 
Serum concentrations of α-defensin (HNP1-3) in 43 patients with AD were measured 
and compared with those of 40 subjects in the control group. Although, there was a high 
individual variation in the serum levels of α-defensin, significant differences were actually 
observed between the healthy subjects and AD patients. The median serum concentrations of 
AD patients were about 147.3 ng/ml, which were significantly higher than those in controls, 
namely 122.3 ng/ml (p < 0.05; see Figure 14). 
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Figure 14. Serum levels of HNP1-3 in Alzheimer’s disease 
4.10 Levels of HNP1-3 in cerebrospinal fluid in AD 
The concentrations of HNP 1-3 in the CF of 52 AD patients were measured and 
compared with 40 control CF samples. As can be seen, higher concentrations of HNP 1-3 
were measured in the CF of AD patients (median concentration 85.16 ng/ml) than in the CF of 
those in the control group (1.23 ng/ml, p<0.001; see Figure 15). 
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Figure 15. CF levels of HNP1-3 in patients with Alzheimer’s disease 
39 
 
5. DISCUSSION 
5.1 The MTHFR A1298C variant in leukoaraiosis 
Previous studies demonstrated that an elevated serum homocysteine level may be 
associated with LA. Also, an elevated serum homocysteine level is presumed to be associated 
with an endothelial dysfunction or microangiopathy. 106 The genetic studies relating to the 
MTHFR C677T variant suggest that, although the 677T variant is unfavourable because it 
raises the serum homocysteine level, it does not increase the risk of contracting LA if it is 
present on its own. We also demonstrated earlier that the 677T variant in combination with 
other genetic variants increases the risk of contracting LA. 15 
The present study reveals that a person carrying either a heterozygous A1298C or a 
homozygous 1298CC variant is at a higher risk of contracting LA than one carrying neither of 
them. This genetic variant has not been examined so far in any LA case–control study. Our 
findings therefore suggest for the first time that the A1298C variant may be more important 
than the C677T variant in the evolution of LA. We also found that the heterozygous C677T 
and A1298C variants do not pose a risk of contracting LA if they are present by themselves. 
However, their combination in the same person leads to a marked risk of contracting LA. 
Here, although the number of patients displaying the combination of the two heterozygous 
MTHFR variants was low, the significance level relating to the approximately tenfold 
increase in the unfavourable combination in the LA group compared with that in the control 
group suggests that there is a definite link. At present the exact cause of this synergistic effect 
is not known. However, two possible explanations readily emerge. They are: (1) the two 
variants can potentially increase the serum homocysteine level in an additive manner and (2) 
the co-occurrence of the two unfavourable MTHFR genetic variants may influence the 
regulation of the enzyme. A properly balanced regulation of the MTHFR may be a key factor 
that can define the daily shifts in the serum homocysteine level. The clustering of the A1298C 
and C677T variants might give rise to an unfavourable regulatory nature in the dynamically 
changing activity of the MTHFR. Then the presence of the two heterozygous variants might 
result in a significantly unfavourable phenotype of the conformation of the enzyme protein. 
5.2 The absolute number of mitochondria per cell in leukocyte cells in leukoaraiosis 
The basic contents for mDNA and dmDNA were found to be statistically the same in 
the LA group and control group, and the K value was significantly lower for the LA group 
than that for the control group. This suggested that there was a larger proportion of dmDNA 
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present. Having dmDNA may possibly lead to a mitochondrial malfunction in the following 
way: a, lower energy production; b, a lower free radical scavenging capacity; c, a lower rate 
of adaptation to the prevailing demand for energy production; d, a narrower range in the 
adjustment to the prevailing energy demand; e, a lower metabolic function capacity in 
general; f, a greater extent of free radical production; and g, a general malfunction of the 
mitochondrial genetic regulation.   
No genetic or biochemical data is available to suggest which of these postulated 
mechanisms actually exist, but a lower and narrower energy capacity appears probable as the 
main pathomechanism behind LA. It was demonstrated earlier at the molecular level that LA 
can arise from a very slight, but chronic level of hypoxia, which may be caused by various 
environmental and genetic susceptibility factors. 106 Our present findings agree with the 
earlier ones that uncoupling protein genetic variants play a role in the development of LA. 107 
The uncoupling proteins govern the electro-chemical gradient between the inner and outer 
spaces of the mitochondria 107, this gradient being essential for the energy production of the 
mitochondria.  
If dmDNA is associated with any kind of biochemical malfunction, an uncompensated 
and larger proportion of dmDNA in the cells may be unfavourable from an energetic 
viewpoint.  
Our results appear to indicate that the lower the difference between the contents of mDNA 
(which compensates for malfunctions of the dmDNA) and dmDNA, the larger the risk of 
contracting LA in a given individual.  
Overall, the results of our study suggest that the ratio of the dmDNA content and mDNA 
content may play a significant role in the pathogenesis of LA. These results also point to the 
need for new approaches for the examination of mitochondrial contents in other common 
brain disorders.  
Limitations of the study 
1. The numbers of mitochondria in the affected brain tissues could not be examined, as this 
study was a clinical one in a human patient population. Brain biopsies would not have been 
ethical; hence we were unable to identify associations between the numbers of mitochondria 
in different human tissues.   
2. Although we found no apparent change in the number of mitochondria in a small cohort of 
study subjects over several weeks (which involved several turnovers of the mitochondria in 
the white blood cells), insufficient scientific data is available concerning the stability of the 
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absolute numbers of mitochondria in the different tissues. This should be clarified in future 
studies. 
3. In this study, no investigations were carried out to identify the properties of the normal 
functioning of the mitochondria with deletion DNAs.  
However, these limitations do not greatly affect the present results, since they are not directly 
associated with the findings. Moreover, they really should be viewed as open scientific 
questions, that should be addressed in future investigations. 
4. Although the logistic regression statistical method has greatly decreased the confounding 
effects of the clinical factors such as age, hypertension 108, 109 and diabetes mellitus 110, the 
results need to be confirmed using a larger population group.  
5.3 Genetic polymorphisms of human β-defensins in patients with multiple sclerosis 
In our present study, an association between human β-defensins and multiple sclerosis 
was found. By investigating three SNPs of DEFB1, the distributions of the C-44G genotypes 
were found to be different between patients with MS and those in the healthy control group, 
while the frequency of the GG genotype was significantly higher in the control population. 
This suggests that the presence of the G allele most likely leads to strengthened HBD1 
antimicrobial activity, which is less frequent among patients with MS. The G allele of C-44G 
SNP generates a putative binding site for nuclear factor B (NF-B) and in all likelihood 
induces overexpression. The proposed effect of this SNP could partly explain why the GG 
genotype was considered to be a protective genotype in atopic dermatitis and also a 
contributory factor in the susceptibility to Candida colonisation in diabetic patients. 111 By 
contrast, in these studies, subjects carrying the CC genotype at the -44 locus site of the gene 
were at a greater risk of becoming infected. It was recently suggested that the C allele of 
DEFB1 C-44G SNP probably abrogates NF-B -dependent DEFB1 up regulation. 112 
The above findings are consistent with our present observation that the GG phenotype 
might also play a protective role in MS, and vice versa, and the higher frequency of the CC 
genotype might be connected with a lower expression of human defensin β-1. Among the 250 
patients with MS, only 9 (4%) had GG homozygote and 62% of the patients had CC 
homozygote, in contrast with 45% of the control group that had CC homozygote. These 
observations appear to emphasise the importance of DEFB1 polymorphisms in MS. 
Similarly, the production of the inducible hBD-2 is lower in MS patients. It is suggested that 
the significantly lower frequency of the copy number of DEFB2 might be one of the reasons 
for the decreased levels of circulating hBD2 in the blood samples of patients with MS. 
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When the association between the copy numbers and the plasma levels of hBD2 was 
investigated, a correlation between the ELISA results and copy number genotypes was found 
in the control group, but not in the groups of patients with MS. Moreover, the low hBD2 
levels correlated nicely with the low frequency of copy numbers (i.e. <4 copy) in the control 
group, but not in the groups of patients with MS. The low hBD2 levels correlated nicely with 
the low frequency of copy numbers (i.e. <4 copy), but in the patients with copy numbers >4, 
the plasma levels of hBD2 did not seem to be elevated. We suppose that other factors not yet 
defined might be responsible for the low levels of hBD2 even in the case of higher copy 
numbers. We hypothesise that abnormalities in the production and the function of human 
defensin-β might be connected with an altered microbiome in MS, as suggested in a recent 
study. 88  
While it is unclear whether enteric microbiota affects human MS, a higher proportion 
of MS patients exhibited antibody responses against gastrointestinal antigens that those in 
with healthy control subjects. This might indicate an altered gut microbiome and immune 
status. 113 
In addition, as β defensins can be produced not only by epithelial cells, but also by astrocytes, 
and microglia cells 74 79, their importance in the central nervous system (CNS) needs to be 
taken into account. Human defensin-β might function as an initial line of defence within the 
CNS either as an antimicrobial, or an immunomodulator, or both. 88 What is more, these 
defenins may also be neuroprotective through their ability to inhibit cellular apoptosis in the 
CNS. 88 
The extreme low frequency of the GG genotype of the C-44G SNP of DEFB1, the 
high frequency of the low copy number (<4) of DEFB2, and the significantly decreased 
plasma levels of hBD2 in patients highlight the importance of human defensin-β levels in MS 
patients. 
Further studies are necessary to elucidate the precise way the impaired function of human 
defensin-β influences the pathomechanism of multiple sclerosis.  
5.4 Association between human defensin β-2 and AD, and between human defensin-α 
(HNP 1-3) and AD 
Higher concentrations of the inducible hBD-2 were found in the cerebrospinal fluid 
and in the sera of AD patients. It is suggested that the significantly higher frequency of the 
copy number of DEFB4, encoding hBD2, might be one of the reasons for the increased levels 
of circulating hBD2 in the blood samples and in the CF of patients with MS.  
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As β defensins can be produced not only by epithelial cells, but also by astrocytes, and 
microglia cells 114 115 their importance in the CNS should be taken into consideration in future 
studies. Human defensin-β might function as an initial line of defence within the CNS either 
as an antimicrobial, or an immunomodulator, or both. 50  
In addition, the contribution of the microbiota to AD pathogenesis was recently 
investigated 109 and it supports the hypothesis of a microbiome-brain axis. Here, microbiome 
means the collective genomes of total microbiota. Recent studies have also begun to clarify 
the degree of involvement of microbiome in AD pathogenesis. It was found that the 
composition of the human microbiome and exposure to pathogens varies with age, diet, 
lifestyle and biological environment. Studies indicate that incidence of AD and microbiome 
exposure and complexity vary greatly in different human populations. 48 49 Here, the 
participation of defensins in AD should not be neglected.  
An elevated hBD expression in the CF suggests that brain synthesises antimicrobial 
peptides and they circulate throughout the ventricular system and protect the CNS against 
microbial infection. 80 Choroid plexus regulates immune functions between peripheral and 
brain circulation, and it is well documented in AD neuropathology (epithelial cell atrophy, 
impaired secretory and transporter functions, reduced amyloid β clearance). The dysfunction 
of the choroid plexus may give rise to neuropathological and inflammatory processes. 79 In 
vitro results suggest that astrocytes may be responsible for local hBD-2 synthesis in the brain. 
115 Astrocytes and microglia are important in the cerebral neuroinflammatory response, and in 
vitro they express hBD-1 and -2; and they may modulate adaptive immunity. Williams et al. 
found a significant elevation of the hBD-1 mRNA level in the chorioid plexus, and increased 
protein level in hippocampal neurons of an AD brain. 51 The increased hBD-1 expression 
within an AD brain may be a protective response to inflammatory stimuli and potential 
modulator of the host’s innate immune response within the CNS. 51 
 It has been suggested that chronic infections might be initial events in AD 
pathogenesis, which can lead to persistent inflammatory stimuli. The inflammatory response 
thereafter may indirectly lead to the upregulation of amyloid β production. 49 It may well be 
that the induction of defensins is also involved in the amyloid development. Many 
antimicrobial peptides exhibit structural characteristics including β–sheet conformation 
similar to amyloid β that contribute to olygomerization. It should also be mentioned here that 
the existence of the oligomerization of monomeric hBD-2 has now been demonstrated. 116 
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 Not only were the inducible hBD-2 elevated in the cerebrospinal fluid and in the sera of AD 
patients, but  the levels of  HNP1-3 were also higher  both in the sera and in the CF. Our 
findings are in accordance with recent data by Watt et al. in 2015, who reported that 
peripheral α-defensins are elevated in Alzheimer’s disease. However, no measurements of the 
defensins in the CF were included in their study. While copy number polymorphism of the 
DEFB4 gene  has been reported to influence  the production of hBD2 74 117, the secretion of 
HNP 1-3 however  seems to be independent of  the copy number of the DEFA gene 118. Hence 
we did not investigate it here. 
The present study supports the view of the potential role for antimicrobial peptides 
like human α and β defensins in AD pathology; they are pathogen targeting agents in brain 
infections involving AD. Whether the elevated levels of defensins are a consequence of 
inflammation, or they themselves induce neurodegeneration and amyloid formation is 
currently unknown. Further investigations are therefore necessary to elucidate the regulatory 
functions of defensins in the pathomechanism of AD. 
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SUMMARY AND NEW RESULTS 
 
 Our results revealed an association between the A1298C polymorphism of the 
MTHFR gene and leukoaraiosis. A person carrying either a heterozygous A1298C or a 
homozygous 1298CC variant is at a higher risk of contracting LA than one carrying 
neither of them. 
 
 Our study suggests that the ratio of the dmDNA content and mDNA content may be of 
great significance in the pathogenesis of LA. The findings here suggest the need for a 
new perspective when we investigate the mitochondrial contents in other common 
brain disorders.  
 
 The extremely low frequency of the GG genotype of the C-44G SNP of DEFB1, the 
high frequency of the low copy number (<4) of DEFB2, and the significantly 
decreased plasma levels of hBD2 in patients all highlight the importance of the role of 
human defensin-β in MS. 
 
 Human α and β defensins in AD pathology, as pathogen targeting agents, play a role in 
brain infections related to AD. Whether the elevated levels of defensins are a 
consequence of inflammation, or they themselves induce neurodegeneration and 
amyloid formation, is currently not known. 
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Abstract Vascular demyelinization of the white matter of
the brain is referred to as leukoaraiosis (LA). This very
frequent entity is associated with a cognitive decline,
thereby resulting in a deteriorating quality of life. Besides
poorly controlled hypertension and aging, its development
is reported to be associated with an elevated serum homo-
cysteine level. Although the methylenetetrahydrofolate reduc-
tase (MTHFR) C677T genetic variant is associated with an
elevated serum homocysteine level, it has not been proved to
be an independent risk factor for LA. The aim of the present
study was to examine whether the MTHFR A1298C genetic
variant, which is also believed to be unfavorable, is associated
with the presence of LA. The clinical and genetic data on 198
LA patients and 235 neuroimaging alteration-free controls
were analyzed. The presence of the A1298C or the 1298CC
variant was calculated to be a risk factor for LA, as compared
with the absence of both of them. The clustering of the
heterozygous A1298C and C677T variants was proved to
involve the risk of LA. Our results suggest that the MTHFR
A1298C variant confers an independent genetic risk of LA,
and this pathological role may be amplified by the MTHFR
C677T variant.
Keywords Leukoaraiosis . Genetics . Risk factors . Genetic
variants .MTHFR
Introduction
Leukoaraiosis (LA), a neuroimaging term, can be defined
as a condition accompanied by hyperintensive signals in
T2-weighted magnetic resonance imaging (MRI) scans of
the white matter of the brain (Pantoni and Garcia 1997;
Pantoni 2002). LA is presumed to be a very frequent entity:
one quarter of people over the age of 65 are estimated to
carry some degree of LA (van Gijn 1998). Chronic hypoxia
and vascular microcirculation disturbances are presumed to
lie behind LA (Markus et al. 2000; Szolnoki et al. 2007).
LA brings about far-reaching health problems in that it is
definitely associated with a cognitive decline or dementia
(Yao et al. 1992; Ylikoski et al. 1993; Wardlaw et al. 2003;
Pantoni et al. 2006; Inzitari et al. 2007) and the resultant
poor quality of life.
LA is a slowly developing entity, associated with a
number of environmental and genetic factors. Hypertension
and aging are among the most important risk factors. A
chronic endothelial dysfunction or blood–brain barrier
damage, which can result from various clinical and genetic
factors, may be key causative factor of LA (Hassan et al.
2003; Szolnoki 2007).
Besides environmental stress and anatomic alterations
such as hypertension and a decreased density of the brain
microvasculature, the complex interaction of a number of
Z. Szolnoki : I. Szaniszlo :A. Kondacs
Department of Neurology and Cerebrovascular Diseases,
Pándy Kálmán County Hospital,
Gyula, Hungary
M. Szekeres :K. Hitri :Y. Mandi : F. Somogyvari
Department of Medical Microbiology and Immunology,
Faculty of Medicine, University of Szeged,
Szeged, Hungary
E. Nedo
Rethy Pal County Hospital,
Bekescsaba, Hungary
Z. Szolnoki (*)
Pipacs köz 9,
5600 Békéscsaba, Hungary
e-mail: szolnoki99@hotmail.com
J Mol Neurosci
DOI 10.1007/s12031-011-9621-4
genetic susceptibility factors may be presumed behind LA
(Moody et al. 2004; Brown et al. 2007; Khan et al. 2007).
These genetic factors do not appear to exert a major effect
on LA but predispose to or modify its development
(Fornage et al. 2007).
An elevated serum homocysteine level has been reported
to be associated with LA (Clarke et al. 2000; Naka et al.
2006; Censori et al. 2007). In addition to a daily intake of
folic acid, the serum homocysteine level can also be
modified by the functioning of the methylenetetrahydrofa-
late reductase (MTHFR). MTHFR C677T polymorphism
has been demonstrated to be associated with LA if it is
present in combination with the angiotensin-converting
enzyme D allele (Szolnoki et al. 2001). Its presence alone,
however, was not proved to result in LA (Szolnoki et al.
2001, 2007). A second common genetic variant in the
MTHFR gene (A1298C) has also been postulated as an
unfavorable vascular risk factor (Szolnoki et al. 2006).
In this context, the aims of the present study were to
examine whether the MTHFR A1298C genetic variant is
associated with LA and whether there is an unfavorable
synergistic effect between the unfavorable MTHFR 677T
allele and the MTHFR A1298C variants as regards the
frequency of LA.
Methods
Subjects
The 198 study subjects were the same as in our previous
LA study (Szolnoki et al. 2001). The patient selection and
clinical check-up were described earlier (Szolnoki et al.
2001). LAwas defined by Fazekas et al. (1987) as irregular
periventricular hyperintensities extending into the deep
white matter in T2-weighted MRI scans (periventricular
hyperintensities of grade 3) and deep white matter hyperin-
tense signals with initial indications of confluence of the foci
or with large confluent areas in the T2-weighted MRI scans
(deep white matter hyperintense signals of grade 2–3).
(…… CC677); ____ C677T; -----677TT)Fig. 1 Examination of MTHFR
C677T variants. Dotted line,
CC677; continuous line, C677T;
dashed line, 677TT
(…… AA1298; ____ A1298C; ------ 1298CC)
Fig. 2 Examination of MTHFR
A1298C variants. Dotted line,
AA1298; continuous line,
A1298C; dashed line, 1298CC
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The controls consisted of 235 neuroimaging alteration-
free subjects. They were randomly selected from our
practice register with the requirement of negative brain
MRI scans.
The study was approved by the local ethical committee.
DNA Analysis
Genomic DNA was extracted from 200 μl of peripheral
blood anticoagulated with EDTA by the desalting
method (Miller et al. 1988). The genetic variants of
MTHFR A677T and A1298C were identified by a
LightCycler probe system, as described earlier (Szolnoki
et al. 2006). LightCycler examinations are illustrated in
Figs. 1 and 2.
Assessment of Clinical Data
The smoking and drinking habits and the presence of
hypertension or diabetes mellitus were recorded in all
groups. The serum cholesterol and serum triglyceride levels
were also measured and analyzed as important clinical
parameters. Hypertension was diagnosed when the blood
pressure repeatedly exceeded 130 mmHg systolic and/or
85 mmHg diastolic or when the patient was taking
antihypertensive medication. Diabetes mellitus was diag-
nosed when the glucose level was at least 7.78 mM in a
fasting state and/or at least 11.11 mM 2 h after a meal or a
75-g oral glucose load according to the World Health
Organization criteria (WHO 1985). Ischemic heart disease
was diagnosed when a history of angina pectoris or acute
myocardial infarction was present or if there was ECG
evidence of coronary heart disease.
Patients were classified as smokers if they had ever
smoked more than five cigarettes per day for at least a year.
Patients were considered to be moderately heavy drinkers if
they drank 40 g of alcohol or more per day. The body mass
index (BMI) was calculated as the weight in kilograms
divided by the square of the height in meters.
Statistics
The clinical data were expressed as means ± SD where
appropriate. The differences between the clinical parame-
ters in the stroke group and the controls were assessed by
using the χ2-test or the Mann–Whitney test where
appropriate. As a first step, we analyzed whether the
MTHFR A1298C variant was a risk factor for LA. Since
MTHFR C677T was not found to be an independent risk
factor for LA in our earlier study, analysis of the
distribution of the C677T variant was not a primary goal.
However, as a second step, we analyzed whether the
presence of the C677T variant had a modifying effect if it
Table 1 Major clinical and laboratory data on patients and control
subjects
Clinical features Leukoaraiosis group
(n=198)
Control group
(n=235)
Sex, females/males 105/93 127/108
Age, years 64.9±9.23* 54.7±12.8
BMI, kg/m2 24.3±2.3 24.6±1.98
Cholesterol, mM 5.41±1.32 5.12±1.34
Triglycerides, mM 1.45±1.59 1.38±0.96
Hypertension 69.7%** 18.7%
Diabetes mellitus 15.2% 13.2%
Smokers 15.2% 11.9%
Drinkers 6.1% 4.3%
Ischemic heart disease 10.1% 6%
The overall stroke group was compared with the control group by the
χ2 -test or the Mann–Whitney test where appropriate
BMI body mass index
*p<0.001; **p<0.0005
Table 2 Distribution of the different genotypes among the participants
Genotypes Leukoaraiosis, n=198 Controls, n=235 p Adjusted ORa 95% confidence interval
MTHFR AA1298 91 (46%) 132 (56.2%) <0.034 0.63 0.42–0.82
MTHFR A1298C 89 (44.9%) 85 (36.2%) NS NS NS
MTHFR 1298CC 18 (9.1%) 18 (7.6%) NS NS NS
MTHFR A1298C +1298CC 107 (54.1%) 103 (43.8%) <0.034 1.6 1.2–2.5
MTHFR CC677 70 (35.4%) 94 (40%) NS NS NS
MTHFR C677T 98 (49.5%) 113 (48%) NS NR NR
MTHFR 677TT 30 (15.1%) 28 (12%) NS NR NR
The stroke groups were compared with the controls by the χ2 -test
NS not significant, NR not relevant
a Adjusted OR was calculated after adjustment for differences in age and hypertension between controls and leukoaraiosis groups
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was in combination with the MTHFR A1298C variant. The
frequencies of the genetic variants were compared with the
χ2-test.
After univariate statistical analysis, we also carried out
logistic regression calculation in order to adjust the differences
in significant clinical risk factors (age and hypertension)
between the LA subjects and the controls. Logistic regression
analyses were performed with the statistical package SYSTAT
10 (Chicago, USA) for Windows.
Results
The clinical parameters are presented in Table 1. The
presence of the 1298C variant (heterozygous A1298C or
homozygous 1298CC) was found to be an independent risk
factor for LA (54.1% vs 43.8%; adjusted OR, 1.6; 95%
confidence interval, 1.2–2.5; p<0.034). Similarly as in our
previous papers, the MTHFR T677C variant was not
calculated to be a risk factor for LA. The distribution of
the different genetic variants is given in Table 2.
The presence of the heterozygous T677C or A1298C
variants did not predispose to LA if they occurred alone.
However, the clustering of both heterogeneous variants in
the same person meant a significant moderate risk of LA
(4% vs 0.4%; adjusted OR, 79.5; 95% confidence interval,
1.2–98.5; p<0.008; Table 3). Data relating to the combina-
tions of the two variants are to be found in Tables 4 and 5.
Discussion
Previous studies and the clinical data demonstrated that an
elevated serum homocysteine level can be associated with
LA. An elevated serum homocysteine level is presumed to
be associated with an endothelial dysfunction or micro-
angiopathy (Szolnoki 2007). The genetic studies relating to
the MTHFR C677T variant suggest that, although the 677T
variant is unfavorable by increasing the serum homocys-
teine level, it does not imply a significant risk of LA if it is
present alone. We earlier demonstrated that the 677T variant
in combination with other genetic variants may confer a
risk of LA (Szolnoki et al. 2001).
The present study reveals that a person carrying either a
heterozygous A1298C or a homozygous 1298CC variant is
at a higher risk of LA relative to one carrying neither of
them. This genetic variant has not been examined so far in
any LA case–control study. Our findings therefore suggest
for the first time that the A1298C variant may be more
important than the C677T variant in the evolution of LA.
We also found that the heterozygous C677T and A1298C
variants do not pose a risk of LA if they are alone.
However, their combination in the same person leads to a
marked risk of LA. Although the number of patients
displaying the combination of the two heterozygous
MTHFR variants was low, the significance level relating
to the approximately tenfold more frequent occurrence of
the unfavorable combination in the LA group as compared
with that in the control group suggests a valid association.
The exact cause of this synergistic effect is not known. Two
possible explanations immediately emerge: (1) the two
variants can potentially increase the serum homocysteine
level in an additive manner and (2) the co-occurrence of the
two unfavorable MTHFR genetic variants may influence the
regulation of the enzyme. A properly balanced regulation of
the MTHFR may be a key factor which can define the daily
shifts in the serum homocysteine level. The clustering of the
A1298C and C677T variants might give rise to an unfavorable
regulatory nature in the dynamically changing activity of the
MTHFR. The presence of the two heterozygous variants
might result in a significantly unfavorable phenotype at the
level of the conformation of the enzyme protein.
Table 3 Synergistic interaction between the heterozygous MTHFR A1298C and C677T genotypes
Genotypes Leukoaraiosis, N=198 Controls, N=235 P Crude OR, 95% confidence interval
MTHFR A1298C + C677T 8 (4%) 1 (0.4%) <0.008 79.5 (1.22–98.5)
The stroke groups were compared with the controls by the χ2 -test
Table 4 Distribution of the different genotypes among the controls
Genotypes MTHFR
1298AA
MTHFR
A1298C
MTHFR
1298CC
MTHFR CC677 36 43 15
MTHFR C677T 71 41 1
MTHFR 677TT 25 1 2
Table 5 Distribution of the different genotypes among the leukoar-
aiosis patients
Genotypes MTHFR
1298AA
MTHFR
A1298C
MTHFR
1298CC
MTHFR CC677 23 32 15
MTHFR C677T 46 49 3
MTHFR 677TT 22 8 0
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Both theories are difficult to check on. The once-
measured serum homocysteine level does not reveal the
nature of its daily fluctuations. LA develops during a very
long period. In this respect, either the average of the serum
homocysteine level or the nature of the changes in the
serum homocysteine appears to be of great importance. The
protein activity or regulation theory can be solved only with
the help of proteomics.
Following are the strengths of the study: (1) The control
subjects were neuroimaging alteration-free, which is highly
important because one quarter of the population over the
age of 65 may be carriers of LAwithout clinical complaints,
and such subjects may well confound the valid difference
between the LA group and true controls. This problem may
have a particular impact as regards minor genetic variants
such as MTHFR A1298C and (2) the logistic regression
approach clearly proved that the A1298C variant is an
independent risk factor for LA. A univariate statistical
approach may lead to false conclusions in view of the
confounding effects of hypertension and age.
The limitations of the study are as follows: (1) The
interaction between the MTHFR A1298C and C677T
variants requires confirmation with regard to the low
number of combinations of the two genetic variants and
(2) the presence of other modifying genetic variants,
e.g., in the angiotensin-converting enzyme, may change
the association.
As this paper is the first relating to this association in
LA, the findings demand confirmation for independent
studies.
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Célkitûzés – Az újabb vizsgálati eredmények kezdenek
rávilágítani a mikrobiom szerepére a sclerosis multiplex
patogenezisében. Azt is feltételezik, hogy a neuropatológiai
változások összefüggésben állhatnak az antimikrobiális pep-
tidek (AMP), köztük a defensinek rendellenes expressziójával
és szabályozó funkciójával. Vizsgáltuk a DEFB1 gén egynuk-
leotidos polimorfizmusának és a DEFB4 gén kópiaszám-
polimorfizmusának a jelentôségét sclerosis multiplexben.
Módszerek – A DEFB1-polimorfizmusokat – c.-20G > A
(rs11362), DEFB1 c.-44C > G (rs1800972), DEFB1 c.—
52G>A (rs1799946) – és a DEFB4-gén kópiaszámát vizs-
gáltuk 250, sclerosis multiplexben szenvedô beteg esetében.
Kontrollcsoportonként 232, életkor és nem szerint illesztett
egészséges véradó szolgált. ELISA-val határoztuk meg a
humán β-defensin 2 peptid (hBD2) elôfordulását a kontrol-
lok és a betegek plazmájában.
Eredmények – A DEFB1 c.-44C>G GG protektív genotí-
pusa ritkábban fordult elô a betegek, mint a kontrollok cso-
portjában. A DEFB4-gén kisebb (<4) kópiaszámának a
nagyobb frekvenciáját figyeltük meg a betegek, mint a kont -
rollok esetében (43% vs. 28%). A keringô hBD2 szintjének
mediánja a betegek esetében 150,6±12,71 pg/ml, a kont -
rollcsoportban 262,1±23,82 pg/ml volt (p<0,0001). Az
eredményeink szerint a β-defensinek szerepet játszanak a
sclerosis multiplex kialakulásában.
Kulcsszavak: humán β-defensinek, kópiaszám, 
polimorfizmus, sclerosis multiplex
Aims – Recent studies have started to elucidate the contribu-
tion of microbiome to the pathogenesis of multiple sclerosis
(MS). It is also supposed, that neuropathological alterations
might be associated with abnormal expression and regulato-
ry function of antimicrobial peptides (AMPs), including
defensins. It is in our interest to investigate the relevance of
the single nucleotide polymorphisms (SNPs) of the DEFB1
gene and the copy number polymorphism of the DEFB4
genes in MS. 
Methods – DEFB1 polymorphisms: c.-20G > A (rs11362),
DEFB1 c.-44C > G (rs1800972), DEFB1 c.-52G>A
(rs1799946), and the DEFB4 gene copy number were inves-
tigated in 250 MS patients The control patients comprised
232 age- and gender-matched healthy blood donors. The
occurrence of the human β-defensin 2 peptide (hBD2) in the
plasma of controls and patients was determined by ELISA. 
Results – The DEFB1 c.-44C>G polymorphism the GG pro-
tective genotype was much less frequent among patients
than among the controls. A higher frequency of a lower (<4)
copy number of the DEFB4 gene was observed in the
patients with MS as compared with the controls (43% vs.
28%, respectively). The median levels of the circulating hBD2
in the patients were 150.6±12.71 pg/ml vs. 262.1±23.82
pg/ml in the control group (p<0.0001). Our results suggest
that β-defensins play role in the development of MS.
Keywords: human β-defensin; copy number; 
polymorphism; multiple sclerosis
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Multiple sclerosis (MS) is a devastating neu-roinflammatory disorder of the brain and the
spinal cord. MS pathogenesis involves inflamma-
tion, neurodegeneration and demyelinisation1. The
main pathological symptoms of the disease are the
destruction of the myelin sheats of nerve fibers, the
relative sparing of the axons, and the infiltration of
inflammatory cells in a perivascular surrounding2, 3.
Although the well-defined autoimmune activities of
the variant types against the central nervous system
(CNS) are of great importance in the process of the
disease, the pathomechanism and the direct
causative factors have not yet been explained. The
disease is defined by combination of exogenous fac-
tors and genetic background.
The contribution of the microbiota to MS patho-
genesis has recently been investigated4. Viral infec-
tions, such as Epstein-Barr virus, or human her-
pesvirus 6 has been suspected as trigger for MS5.
Accumulating informations strengthen the concept
of microbiome-brain axis6. Microbiome refers to
the collective genomes of total microbiota. Recent
studies have started to elucidate the contribution of
microbiome to MS pathogenesis, which is being
investigated in EAE models work. In addition, the
recent trend of research has focused on the role of
natural antimicrobial peptides in CNS disorders. It
is supposed, that neuropathological alterations
might be associated with abnormal expression and
regulatory function of antimicrobial peptides
(AMPs), including defensins7.
Defensins and defensin-like proteins are fairly
universal participants in host defence against infec-
tion8. Defensins are small cysteine-rich peptides
that can be classified as either α-defensin or β-
defensin, depending upon the arrangement of six
critical cysteine residues9 Defensins have activity
against Gram-positive and –negative bacteria,
viruses (adenovirus, herpes virus, influenza virus,
cytomegalovirus, HIV-10 and fungi, with minimal
inhibitory concentrations in the µg ml-1 range11. The
most frequently studied antimicrobial peptides are
the human β-defensins (hBDs)12. The β-defensins
are directly antimicrobial, and that microbial
pathogens and pathogen induced cytokines stimu-
late their expression. The expression of hBDs can
be stimulated by interleukin-1α (IL-1α), IL-1β,
tumor necrosis factor-α (TNF-α), interferon-γ
(INF-γ)13, 14. Then again, β-defensins induce the
production of different chemokines and cytokines
such as macrophage inflammatory protein 3-α
(MIP-3α), interferon inducible protein 10, IL-1, IL-
6, IL-10 and TNF-α10, 15. The β-defensins comprise
the largest group, with around 40 members encoded
in the human genome16, but most studies have
focused on HBD1 and HBD2. The expression of
HBD1 is generally essential, the level of HBD2 is
raised by proinflammatory cytokines and bacte -
ria17, 18. Human β-defensins are produced by epithe-
lial cells of the skin, gut, respiratory and urogenital
tissue. HBD1 is also expressed by leukocytes.
HBD1 mRNA has been observed in human astro-
cytes and microglia cells19. Furthermore, epithelial
cells, the expression of HBD2 has been detected in
human monocytes, macrophages, and dendritic
cells20. Astrocytes may be other ways of local
HBD2 synthesis in the brain19. The generally syn-
thesized defensins, as antimicrobial peptides
(AMPs) may protect the brain against bacterial or
viral infections. It is noteworthy, however, that the
antimicrobial function of AMPs might actually sec-
ondary to their immunomodulatory properties21.
The level of defensin expression varies among
individuals and it has been suggested that this vari-
ation is due to genetic differences in the genes
encoding defensins. Defensin genes have been
mapped to 8p22-p2322. Two types of genetic poly-
morphisms have been identified in genes encoding
defensins, copy number polymorphisms and single
nucleotide polymorphisms (SNPs). Human
defensin beta-1 (HBD-1) encoded by the gene
DEFB1, in which several SNPs (single nucleotide
polymorphisms) have been characterized. Three
frequent SNPs at positions G-20A (rs11362), C-
44G (rs 1800972) and G-52A (rs1799946) in the 5’-
untranslated region (UTR) of DEFB1 were
described23. The untranslated variants influence
HBD-1 expression or function24.
The β-defensins are found to be impaired in
many inflammatory diseases, including Crohn’s
disease, psoriasis, pulmonary inflammation25, 26,
and periodontal disease11. β-defensins have been
hypothesized to play a role in the aetiology of neu-
rodegeneration with a focus on traumatic brain
injury, a risk factor for Alzheimer’s disease
(AD)27. A role of HBDs genes as potential modi-
fiers in multiple sclerosis (MS) has not been
hypothesized previously. It has been published
that commensal bacteria within the gut can direct-
ly control the development of EAE, the experi-
mental model of human multiple sclerosis by a
combination of regulatory and antiinflammatory
cell populations28. It can be speculated, that the
induction of defensins might also be involved in
this process. Therefore, it is in our interest to
investigate the relevance of the SNPs of the
DEFB1 gene and the copy number polymorphism
of the DEFB4 genes in MS.
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Materials and methods
PATIENTS
The study included 250 MS patients. The examined
population contained 197 RR (relapsing remitting)
and 53 SP (secondary progressive) persons with a
mean age of 44.23±13.02 years. Patients were diag-
nosed and collected from the Department of
Neurology at the University of Szeged and
Department of Neurology of Pándy Country
Hospital in Gyula. The criterion was a diagnosis of
clinically definitive MS29. The RR type was
described as the presence of exacerbations followed
by complete or partial remissions. The SP form was
defined as the presence of a slow deterioration of
the disability lasting for more than six months, with
or without relapses, in subjects to who - before the
progressive phase - had exhibited a RR course30.
The clinical classification was supported by the
MRI criteria31, 32. MRI protocols were materialized
in accordance with the European Concerted Action
Guidelines32. The expanded disability status scale
score (EDSS) for the study population ranged from
0 to 8 (mean, 3.37±1.94) with a disorder duration of
less than 1-20 years (mean, 8.83±2.16 years). All
patients have given informed consent to their par-
ticipation in this study, and the local ethics commit-
tees – Human Investigation Review Board at the
University of Szeged Albert Szent-Györgyi
Medical and Pharmaceutical Centre and the Human
Investigation Review Board of Pándy Country
Hospital, Gyula – have given prior approval to the
study.
The control patients comprised 232 age and gen-
der-matched healthy blood donors. The control
group was selected from blood donors at the
Regional Centre of the Hungarian National Blood
Transfusion Service, Szeged Hungary. The charac-
teristics of MS patients and controls are presented
in Table 1.
DNA ISOLATION
Genomic DNA was extracted from 200 µl of periph-
eral blood anticoagulated with EDTA by the manu-
facturer’s instructions (High Pure PCR Template
Preparation Kit; Roche Diagnostic GmbH,
Mannheim, Germany, Cat.no: 1796828). The
genomic DNA was stored at -20 °C until further
use.
GENOTYPING
Human β-defensin 1 (DEFB1) – Genotyping was
carried out Custom TaqMan® SNP Genotyping
Assays (Applied Biosystems, Foster City, CA,
USA). Fluorogenic minor groove binder probes
were used for each case using the dyes-6-carboxy-
fluorescein FAM (excitation 494 nm) and VIC
(excitation 538 nm): DEFB1 polymorphisms: c.-
20G > A (rs11362) Applied Biosystems code
c_11636793_20, DEFB1 c.-44C > G (rs1800972)
c_11636794_10, and DEFB1 c.—52G>A
(rs1799946) c_11636795_20. Thermal cycling was
performed on Bio Rad CFX96TM Real-Time PCR
system. The amplification mix contains the follow-
ing ingredients: 6 µl of Maxima® Probe/ROX qPCR
Master Mix (Fermentas, Vilnius, Lithuania), 0.3 µl
of primer-probe mix, 5.1 µl of RNase and DNase-
free water (Fermentas, Vilnius, Lithuania), and 1 µl
of sample DNA, in a total volume of 11.4 µl per sin-
gle tube reaction. Assay conditions were 10 min at
95 °C, and 40 cycles of 95 °C for 15 s and 60 °C for
1 min. Each 96-well plate contained 93 samples of
an unknown genotype and three reactions with
reagents but no DNA. DNase-free water was used
as non-template control. Initial and post assay
analyses were performed using the Bio Rad
CFX96TM Real-Time system Precision Melt
AnalysisTM Software.
Determination of DEFB4 Gene Copy Number –
A TaqMan real-time PCR assay, specifically for
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Table 1. Characteristics of patients and controls
Clinical parameters Relapsing- Secondary Overall MS, Controls, 
remitting MS, progressive MS, N=250 N=232
N=197 N=53
No. of patients (male/female) 49/148 16/37 65/185 168/64
Age (years) (means, SD) 45.7±14.5 56.75±12.68 44.23±13.02 46.8±11.98
Disease duration (years) (means, SD) 10.36±10.02 7.3±4.7 8.83±2.16 Not relevant
EDDS score (means, SD) 2.36±1.48 5.5±1.39 3.37±1.94 Not relevant
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amplification of genomic DEFB4, was materialized
by using a specific set of amplification primers (for-
ward 5’-TGAAGCTCCCAGCCATCAG-3’; re -
verse 5’-TATTTCCCTGGCCCATCTCA-3’ and a
VIC-labeled probe 5’- VIC- ATCTCCTCTTCT -
CGTTCC-MGB). Quantitative DEFB4 amplifica-
tion data were normalized to ABL [FAM-lebeled
albumin (Applied Biosystems, Cat. No. 4331182)]
as an internal reference gene, which was added to
each single tube. DEFB4’s primers and probe were
designed using Primer Express 3.0 (Applied
Biosystems). Probes were purchased from Applied
Biosystems, and primers were obtained from
Invitrogen (Carlsbad, CA, USA). Real-time PCR
was carried out the Bio Rad CFX96TM Real-Time
PCR system. Amplifications were performed in
triplicate with Maxima® Probe /ROX qPCR Master
Mix (Fermentas, Vilnius, Lithuania), 20 ng of tem-
plate DNA, 300 nM per primer, 200 nM of each flu-
orogenic probe. Steps of thermal cycling were 10
min at 95 °C, and 40 cycles of 95 °C for 15 s and 60
°C for 1 min. Quantification was evaluated by the
comparative CT (Threshold Cycle) method33. 
ELISA OF HUMAN B-DEFENSIN 2
ELISA of human β-defensin 2 (hBD2) (Alpha
Diagnostic San Antonio, TX, USA) was used to test
for the occurrence of the human β-defensin 2 pep-
tide in the plasma of controls and patients, on the
basis of manufacturer’s instructions. The detection
limit of the hBD2 ELISA Kit was 0.8 pg hBD2 pro-
tein/ml.
STATISTICAL ANALYSIS
The significance of the genotype frequency was
analysed by the chi-square test and the Fisher test.
The rate of significance was P<0.05. The genotype
frequencies of SNPs were tested for deviation from
the Hardy-Weinberg equilibrium by the chi-square
test, with one degree of freedom. Plasma levels of
human β-defensin 2 are expressed as medians with
the Mann-Whitney test. The group means were dis-
criminated by ANOVA test and followed by
Bonferroni’s multiple comparison test. 
The GraphPad prism 5 statistical program was
used to all statistical calculations (GraphPad
Software Inc. San Diego, CA, USA). 
Results
DEFB1 C.-20G<A, DEFB1 C.-44C>G, AND DEFB1 C.-52G>A
POLYMORPHISMS
The total number of MS patients in these genotyp-
ing experiments was 250 and the control group con-
tained 200 healthy members. The three genotypes
of DEFB1 and the controls patients were in accor-
dance with the Hardy-Weinberg equilibrium
(DEFB1 c.-20G>A P=0.677 and in the control
group P=0.912; DEFB1 c.-44C>G P=0.999 and in
the controls P=0.723; DEFB1 c-52G>A P=0.657
and in the control group P=0.253 respectively). 
The genotypic distributions of DEFB1 c.-
20G<A, DEFB1 c.-44C>G, and DEFB1 c.-52G>A
polymorphisms are presented in Tables 2–4. 
There was no significant difference in genotype
distribution between the DEFB1 c.-20G>A and the
controls (P=0.4106). Similarly, no significant dif-
ferences in genotypes between the DEFB1 c.-
52G>A and the healthy patients (P=0.766). In the
case of the DEFB1 c.-44C>G polymorphism there
was significant difference in genotypes distribution
between the patients and the control group
(P=0.0002; Table 3. and Figure 1.). 
130 Szekeres: Genetic polymorphisms of human β-defensins in patients with multiple sclerosis
Table 2. Distribution of DEFB1 c.-20G>A genotypes in MS
patients
GG (%) GA (%) AA (%) χ2 test*
Patients with MS 78 (31) 131 (53) 41 (16) 0.4106
n=250
Controls n=200 62 (31) 96 (48) 42 (21)
*chi square test vs. controls
Table 3. Distribution of DEFB1 c.-44C>G genotypes in MS
patients
CC (%) CG (%) GG (%) χ2 test*
Patients with MS 
n=250 160 (64)++ 80 (32) 10 (4) + 0.0002
Controls n=200 90 (45) 92 (46) 18 (9)
* chi square test vs. controls
+ Fisher test: P=0.0317; OR=2.384; CI=1.074-5.288
++ Fisher test: P<0.0001; OR=0.465; CI=0.318-0.680
Table 4. Distribution of DEFB1 c.-52G>A genotypes in MS
patients
GG (%) GA (%) AA (%) χ2 test*
Patients with MS 100 (40) 111 (44) 39 (16) 0.766
n=250
Controls n=200 80 (40) 84 (42) 36 (18)
*chi square test vs. controls
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COPY NUMBER POLYMORPHISM OF DEFB4
The determination of copy number (CN) was per-
formed in 250 patients in the MS group and in 232
healthy controls. The range of copy numbers was
between two and eight per genome in the control
group. Four copies were the median number of the
healthy controls. The proportions of control indi-
viduals who carried the median (4), more than
median (>4), or less than the median (<4) number
of copies were 39%, 33%, 28%, respectively. In the
patients with multiple sclerosis, the frequency dis-
tribution of the subgroups was different from the of
the control group (P=0.002, Figure 2.). Among the
patients with MS, 43% had a lower (<4) copy num-
ber compared to the controls. The frequency of a
CN >4 was only 27% among the patents with MS
and 33% among the controls. As suggested, the
copy numbers were higher than 4, the difference
between MS patients and controls was not statisti-
cally significant, however, there was a lower fre-
quency among patients (27%) than in the controls
(33%) (Figure 2.).
PLASMA LEVELS OF HBD2
ELISA for hBD2 was performed from samples of
patients with MS and controls with known CNs of
DEFB4, to determine whether the plasma levels of
hBD2 varied with respect to the CN variation of the
DEFB4 gene. The level of human β-defensin 2 in
MS patients (n=80) were significantly lower alto-
gether than it was in the controls (n=50). The medi-
an levels of hBD2 in the patients were 150.6±12.71
pg/ml vs 262.1±23.82 pg/ml in the control group,
p<0.0001 (Figure 3.). The circulating levels of
human β-defensin 2 correlated well with the CN in
the control group. Similarly to the controls, the plas-
ma levels were found to be significantly lower in
the <4 CN group (135.3±25.49 pg/ml), compared to
patients with copy numbers of 4 (173.7±44.09
pg/ml). The defensin levels however were not ele-
vated in patients with CN higher than 4 (148.9±
31.21 pg/ml) (Figure 4.).
Discussion
In our present study, an association between human
β-defensins and multiple sclerosis has been found.
By investigating three SNPs of DEFB1, the distri-
butions of the C-44G genotypes were different
between patients with MS and healthy controls,
Ideggyogy Sz 2015;68(3–4):127–133. 131
Figure 1. Distribution of DEFB1 c.-44C>G genotypes
in MS patients and controls. Both the frequency of GG
(*P=0.0317; OR=2.384; CI=1.074-5.288) and the CC
genotypes (**P<0.0001; OR=0.465; CI=0.318-0.680)
vs. controls were significant different according to the
Fisher test
Figure 2. Distribution of DEFB4 gene CN in MS patients
and controls. The frequency of CN <4 was significantly
different between the MS group and the controls accord-
ing to the Fisher test (*P=0.0005; OR=0.507;
CI=0.3464 to 0.7413)
Figure 3. The median levels of hBD2 in the patients
(150.6±12.71 pg/ml) and in the controls (262.1±
23.82 pg/ml). Horizontal lines represent medians.
P<0.0001 according the Mann-Whitney test
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while the frequency of the GG genotype was signif-
icantly higher in the control population. This indi-
cates that the presence of G allele probably leads to
strengthened HBD1 antimicrobial activity, which is
less frequent among patients with MS. The G allele
of C-44G SNP generates a putative binding site for
nuclear factor κB (NF-κB) and very likely induces
overexpression. The proposed effect of this SNP
could partially explain why the GG genotype was
considered to be a protective genotype in atopic der-
matitis and also in susceptibility to Candida colo-
nization in diabetic patients34. Conversely, in these
studies, subjects carrying the CC genotype at the -
44 locus site of the gene were at a greater risk of
acquiring infection. It has been recently suggested,
that the C allele of DEFB1 C-44G SNP probably
abrogates NF-κB -dependent DEFB1 up regula-
tion35.
These data are consistent with our present obser-
vation that the GG phenotype could also be protec-
tive in MS, and vice versa, the higher frequency of
CC genotype might be connected with lower
expression of human defensin β-1. Among the 250
patients with MS only 9 (4%) were GG homozy-
gotes, and 62% of the patients were CC homozy-
gotes, as compared with 45% of CC homozygotes
in the control group. These observations draw atten-
tion to the importance of DEFB1 polymorphisms in
MS.
Similarly, the production of the inducible hBD-2
is lower in MS patients. We suggest that the signif-
icantly lower frequency of the copy number of
DEFB2 might be one of the reasons of the
decreased levels of circulating hBD2 in the blood
samples of patients.
When the association between the copy numbers
and the plasma levels of hBD2 was investigated, a
correlation between the ELISA results and copy
number genotypes was found in the control group,
but not in the groups of patients with MS. The low
hBD2 levels correlated well with the low frequency
of copy numbers (i.e. <4 copy) in the control group,
but not in the groups of patients with MS. The low
hBD2 levels correlated well with the low frequency
of copy numbers (i.e. <4 copy), but in the patients
with copy numbers >4, the plasma levels of hBD2
did not seem to be elevated. We suppose, that per-
haps yet undefined other factors might be responsi-
ble for the low levels of hBD2 even in the case of
higher copy numbers. We hypothesize that abnor-
malities in the production and the function of
human defensin-β might be connected to an altered
microbiome in MS, as it has been suggested recent-
ly6. 
While it is unclear whether enteric microbiota
affect human MS, a higher percentage of MS
patients exhibited antibody responses against gas-
trointestinal antigens in contrast to healthy control,
which could indicate altered gut microbiome and
immune status36.
In addition, β defensins can be produced not only
by epithelial cells, but also by astrocytes, and
microglia cells8, 19, therefore their local importance
in the central nervous system (CNS) has to be taken
into consideration. Human defensin-β might func-
tion as an initial line of defence within the CNS
either as an antimicrobial, or an immunomodulator,
or both6. In addition, these defenins may be also
neuroprotective through their ability to inhibit cel-
lular apoptosis in CNS6.
The extreme low frequency of GG genotype of
the C-44G SNP of DEFB1, the high frequency of
the low copy number (<4) of DEFB2, and the sig-
nificantly decreased plasma levels of hBD2 in
patients underline the importance of human
defensin-β in MS.
Further studies are necessary to elucidate the
exact mechanism on how the impaired function of
human defensin-β influences the pathomechanism
of multiple sclerosis. 
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Figure 4. Plasma levels of hBD2 in MS and in control
group with DEFB4 copy numbers of <4, 4, >4. Data are
means and SD of the results on 50 samples in control
group and 80 in MS patients. Differences between group
means were determined with ANOVA test (difference
between patients and controls P<0.0001) followed by
Bonferroni’s multiple comparison test *CN<4 MS
patients vs. controls P<0.001, **CN=4 MS patients vs.
controls P<0.001, ***CN>4 MS group vs. control
patients P<0.001 
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http://dx.doi.org/10Background and Aims. Leukoaraiosis (LA), one of the most frequent causes of an age-
associated cognitive decline, can be associated with a poor quality of life, leading overall
to far-reaching public health problems. Chronic hypoxia of the white matter of the brain
may be a factor triggering this entity. LA may develop as a consequence of chronically
insufficient cellular energy production and the accumulation of free radicals.
Methods. In this context, after hypothesizing that the number of healthy mitochondria
can be crucial in this complex process, a case-control LA study was carried out in which
we analyzed the numbers of deleted and non-deleted mitochondria (the common D-loop
deletion) per white blood cell. A total of 234 patients with LA and 123 MRI alteration-
free subjects served as a control group.
Results. Interestingly, it emerged that the ratio of deleted relative to non-deleted mito-
chondria is strongly associated with the risk of LA. The calculated K ratio in the LA
group was significantly lower than the K ratio in the controls (LA: K 0.37 95% CI
0.05; controls: K 0.48, 95% CI 0.076, p ! 0.001).
Conclusions. Our study suggests that the ratio of the dmDNA and mDNA can be of great
importance in the pathogenesis of LA.  2015 IMSS. Published by Elsevier Inc.
Key Words: Leukoaraiosis, Mitochondria, Energy production, White matter damage.Introduction
Leukoaraiosis (LA) is originally a neuroimaging term and
refers to hypodensities in CT scans and hyper-intense sig-
nals in T2-weighed MRI scans. Although LA is a neuroi-
maging term, it relates to a complex clinical entity (1e3).
LA has been reported to be associated with a cognitive
decline and a slowing of mental processing, which can be
manifested as a slowness of speech or understanding
(4e6). LA is considered to be a vascular demyelinating
process (7,8). Although it results from factors such as aging
and hypertension (9), development of LA may betributed equally to the work.
quests to: Zoltan Szolnoki, Dr. H-5600 Bekescsaba,
y; Phone/Fax: þ36 66 442904; E-mail: szolnoki99@
nt matter. Copyright  2015 IMSS. Published by Elsevier
.1016/j.arcmed.2015.11.002associated with a number of several genetic susceptibility
factors (10e15).
These genetic and other risk factors suggest that chronic
hypoxia might trigger intracellular biochemical events,
which result in LA (16,17). Accordingly, we hypothesized
that a key role in the demyelinization process of LA may
be played by chronically insufficient energy production
(18). Hence, in addition to certain biochemical features,
the number of mitochondria, the main energy-supplying or-
ganelles in mammalian cells (19), may be deterministic for
the fate of neurons and glia cells. Mitochondrial mutations
can affect different cell types in different ways; this is re-
flected in mitochondria-associated genetic disorders such
as MELAS (20). In such cases, mutations of the mitochon-
drial DNA or tRNA bring about a malfunction in the
affected mitochondria (21). However, virtually no data are
available as concerns the number of the mitochondriaInc.
605Reduced Number of Mitochondria in Leukoaraiosisthemselves, which must be an important feature from an en-
ergetic aspect.
Although the numbers of mitochondria are probably
essential as concerns the neurons and glia cells (17), these
data cannot easily be examined in clinical studies. Howev-
er, the numbers of mitochondria in other tissues, which are
functionally in constant contact with the brain tissue, may
be informative. The white blood cells, for example,
constantly circulate and communicate with the brain tissue.
Their energy store may be important for the maintenance of
the brain because they act as free radical scavengers and
also check on the integrity of the neurovascular system of
the brain (22). The white blood cells, vascular cells and
brain tissue most likely behave as a functional unit. Howev-
er, very few data have been published as regards the
numbers of mitochondria among the different cell types.
The number of mitochondria in the white blood cells may
be an indicator of the overall number of mitochondria in
the given individual.
In this context, we examined whether there is an associ-
ation between the number of mitochondria in the white
blood cells and the development of LA. Besides the genetic
heterogeneity of the mitochondrial DNA (23), there are two
large types of mitochondrial DNA: one with D-loop se-
quences and one without them. The former is known as
mitochondrial DNA (mDNA) and the latter as mitochon-
drial DNA with a large and common deletion of 123-
1256 bp (dmDNA). This latter DNA might be considered
to malfunction in some way (24,25). In our present study
we identified the copy number per white blood cell for both
mDNA and dmDNA.Patients and Methods
Study Population
A total of 234 patients with LA were recruited after a clin-
ical scrutiny. LA was diagnosed on the basis of MRI scans
as described previously (14). Patients with degrees of I or II
on the validated Fazekas LA scale (26) were excluded as
were patients with clinical entities such as multiple scle-
rosis, trauma, postinfectious demyelination, radiationTable 1. Sequences and concentrations of primers and probes
Primer Sequence
GAPDH for 50-TCC AGT ATG ATT CCA CCC ATG GCA-3
GAPDH rev 50-TTC TAC ATG GTG GTG AAG ACG CCA-
GAPDH probe 50-TTC CAT GGC ACC ATC AAG GCT GAG A
mtDNA for 50-ATG GCC AAC CTC CTA CTC CTC ATT-30
mtDNA rev 50-TTA TGG CGT CAG CGA AGG GTT GTA-3
mtDNA probe 50-CGC AAT GGC ATT CCT AAT GCT TAC C
dmtDNA for 50-ACA CAA ACT ACC ACC TTT GGC AGC-
dmtDNA rev 50-TTC GAG TGC TAT AGG CGC TTG TCA-3
dmtDNA probe 50-CCA AAG ACC ACA TCA TCG AAA CCGtherapy, chemotherapy and well-defined hereditary leu-
koencephalopathy because these did not result from
vascular and chronic hypoxia-triggered demyelination.
The patient group consisted of 234 subjects with LA
defined as irregular periventricular hyperintensities extend-
ing into the deep white matter in T2-weighted MRI scans
(grade 3 periventricular hyperintensities) and deep white
matter hyperintensive signals with beginning confluence
of the foci or with large confluent areas in the
T2-weighed MRI scans (deep white matter hyperintensive
grade 2e3 signals).
One hundred twenty three MRI alteration-free subjects
with no neurological complaints recruited from a popula-
tion pool in our regional register served as a control group.
The clinical risk factors, defined as described in an earlier
leukoaraiosis study (27), and basic psychological data were
registered in the controls.
DNA Isolation
Genomic DNA was extracted from 200 ml of peripheral
blood anticoagulated with EDTA. The leukocyte DNA
was isolated by a desalting method (28) and was stored at
20C until further use.
Determination of Absolute Number of Mitochondria per
Leukocyte
The TaqMan real-time PCR assays, specific for the ampli-
fication of mDNA and dmDNA, were established by using
a specific set of primers and probes. Quantitative mDNA
and dmDNA amplification data were normalized to
GAPDH as an internal reference gene, which was co-
amplified simultaneously in a single-tube assay. The
primers were obtained from Sigma-Aldrich (St. Louis,
MO) and the sequences are listed in Table 1. Thermal
cycling was performed on the Bio-Rad CFX96 real-time
PCR system (Bio-Rad, Hercules, CA). Amplification reac-
tions (10 ml each) were performed in duplicate with 1 ml of
template DNA. The amplification mix contained the
following ingredients: 5 ml of iQ Multiplex Powermix
(Bio-Rad), 0.4 ml of each primer, 0.1 ml of each fluorogenic
probe, and 1 ml of sample DNA in a total volume of 10 mlTaqMan signal dyes Conc. (mmol)
0 - 0.4
30 - 0.4
A-30 ROX/BHQ2 0.2
- 0.4
0 - 0.4
G-30 HEX/TAMRA 0.1
30 - 0.4
0 - 0.4
CA-30 FAM/TAMRA 0.1
Table 2. Characteristics of patients and control subjects
Characteristics Leukoaraiosis n [ 234 Controls n [ 123
Sex (females, males) 123, 111 65, 58
Age, years 71.6  10.8a 59.4  8.62
BMI, kg/m2 24.6  2.33 24.4  3.42
Cholesterol, mmol 5.91  1.24 5.52  1.56
Triglycerides, mmol 1.48  0.91 1.50  0.82
Hypertension 46.6%a 22.0%
Diabetes mellitus 17.9%a 4.88%
Smokers 29.9% 28.5%
Drinkers 12.0% 9.0%
ap ! 0.05; the leukoaraiosis group was compared with the control group
by means of the c2 test or Mann-Whitney test.
606 Szolnoki et al./ Archives of Medical Research 46 (2015) 604e608per single-tube reaction. The assay conditions were 3 min at
95C and 44 cycles of 95C for 10 sec and 60C for 45 sec.
Quantification was evaluated by the comparative CT
(threshold cycle) method (29).
Because no data were available concerning the stability
of the number of mitochondria in white blood cells, the
numbers of mitochondria in five patients and five controls
were determined three times with a minimum interval of
1 month between blood drawings in the same subject. We
found merely minimal number differences between the
different blood samples in the same subject (data not
shown).
Statistical Analysis
Clinical variables in the LA and control groups are listed
and compared statistically in Table 2.
mDNA and dmDNA contents per white blood cell in the
LA group were compared with those in the control group by
means of the two-paired T-test (Table 3). In order to make
the comparison biologically more sensitive, the mathemat-
ical difference between the mDNA and mdDNA contents
per cell were derived by the sum of mDNA and dmDNATable 3. Distributions of deleted and non-deleted mitochondrial DNA
contents per cell in the leukoaraiosis and control groups
Genotypes
Leukoaraiosis n [ 234
Controls n [ 123(mean ± 2 SD)
Number of non-deleted
mitochondria per cell
5.5  0.45 5.4  0.5
Number of deleted
mitochondria per cell
3.45  0.5 3.5  0.5
Ka 0.37  0.03 0.48  0.03b
aNon-deleted mitochondrial DNA content per cell minus deleted
mitochondrial DNA content per cell divided by the sum of the contents
of deleted and non-deleted mitochondrial DNA per cell
(K 5 [mDNA  dmDNA]/[mDNA þ dmDNA]).
bp! 0.001: the leukoaraiosis group was compared with the control group
by means of the two-paired t-test.contents per cell in the same individual. This calculated ra-
tio (K) indicated the weight of uncompensated dmDNA per
cell:
K5
ðmDNA content  dmDNA contentÞ
ðmDNA content þ dmDNA contentÞ :
K values for each of the LA patients and the controls were
compared statistically between the LA and control groups
by means of the two-paired T-test (Table 3).
Univariate statistical analysis was followed by a logistic
regression comparison involving the age, hypertension and
diabetes mellitus (due to the statistical difference between
the LA and control groups) in addition to the calculated
values of K.Results
The frequency of hypertension in the LA group was higher
than that in the controls (Table 2). mDNA and dmDNA con-
tent did not differ statistically between the LA and control
groups (Table 3).
The calculated value of K for the LA group was signif-
icantly lower than that for the controls after the used logis-
tic regression analysis. This logistic regression analysis was
carried out for the differences between the LA and controls
with regards to the age, hypertension and diabetes mellitus.
In this way, we could diminish the confounding effects of
these clinical factors because they could also be associated
with the reduced number of mitochondria (LA: K 0.37,
95% CI 0.05; controls: K 0.48, 95% CI 0.076; p! 0.001).Discussion
Although the basic mDNA and dmDNA contents were sta-
tistically the same in the LA and control groups, the value
of K was significantly lower for the LA group than that for
the control group. This was a mathematical indicator of a
larger proportion of dmDNA. dmDNA can potentially
result in a mitochondrial malfunction in the following
ways: (a) lower energy production; (b) a lower free radical
scavenging capacity; (c) a lower rate of adaptation to the
prevailing demand for energy production; (d) a narrower
range in the adjustment to the prevailing energy demand;
(e) a lower of metabolic function capacity in general; (f)
a larger extent of free radical production; and (g) a general
malfunction of the mitochondrial genetic regulation.
No genetic and biochemical data are available to suggest
which of these postulated mechanisms actually exist, but a
lower and narrower energy capacity appears probable as the
main pathomechanism behind LA. It was demonstrated
earlier at a molecular level that LA can result from a very
slight, but chronic, level of hypoxia, which can be caused
by various environmental and genetic susceptibility factors
607Reduced Number of Mitochondria in Leukoaraiosis(16). Our present findings are in accord with the earlier
findings that uncoupling protein genetic variants play roles
in the development of LA (30). The uncoupling proteins
govern the electrochemical gradient between the inner
and outer spaces of the mitochondria (31), this gradient be-
ing essential for the energy production of the mitochondria.
If dmDNA is associated with any kind of biochemical mal-
function, an uncompensated and larger proportion of
dmDNA in the cells can be unfavorable from an energetic
aspect.
Our results revealed that the lower the difference be-
tween the contents of mDNA (which compensates malfunc-
tions of the dmDNA) and dmDNA the larger the risk of LA
in the given individual.
In conclusion, our study suggests that the ratio of
dmDNA and mDNA contents can be of great importance
in the pathogenesis of LA. These results indicate the need
for new approaches for examination of mitochondrial con-
tents in other common brain disorders.
Study Limitations
The numbers of mitochondria in the affected brain tissues
could not be examined because this was a clinical study
carried out in a human patient population. Brain biopsies
would not have been ethical; thus, it remained to identify
associations between the numbers of mitochondria in
different human tissues. Although we found no apparent
change in the number of mitochondria in a small cohort
of study subjects during several weeks (which involved
several turnovers of the mitochondria in the white blood
cells), insufficient scientific data are available concerning
the stability of the numbers of mitochondria in the different
tissues. This should be clarified.
No examinations were carried out in this study to iden-
tify the features of the malfunctioning of the mitochondria
with deletion DNAs. However, these limitations do not
greatly affect the present results because they are not obvi-
ously associated with the findings. Moreover, these postu-
lated limitations are rather scientific questions, which
should be considered in subsequent examinations.
Albeit the logistic regression statistical method has
greatly decreased the confounding effects of the clinical
factors such as age, hypertension (32,33) and diabetes mel-
litus (34), the results need to be confirmed by a larger pop-
ulation study.References
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The DEFB4 gene copy numbers were investigated in 206 AD patients and in 250 controls. The levels of
the human defensin β2 (hBD2) and α-defensins (HNP 1-3) in the sera and in the cerebrospinal ﬂuid
(CSF) of the patients and the controls were determined.
Higher copy numbers of the DEFB4 gene was observed in AD patients as compared with the controls. The
levels of hBD-2 and HNP 1-3 were signiﬁcantly elevated in the sera and in the CSF of the AD patients
These data suggest that both defensin β2 and α-defensins have potential role in the development of AD.
& 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Initiating event in AD is related to the abnormal processing of beta-
amyloid (Aβ), ultimately leading to the formation of Aβ plaques in the
brain (Jack et al., 2010). It was recently postulated that brain infections
involving bacteria or viruses may play an initiating role in amyloid
plaque formation and the development of AD (Hill et al., 2014; Ma-
heshwari and Eslick, 2015; Mawanda and Wallace, 2013). Persistent
subclinical CNS infections have been reported for AD patients, caused
by various pathogens such as Chlamydia pneumoniae, Helicobacter
pylori, Herpes simplex virusI, spirochetes or even fungi (Shima et al.,
2010; Lövheim et al.,2015; Miklossy 2011; Alonso et al., 2014).
It is presumed, that neuropathological alterations might be as-
sociated with abnormal expression and regulatory function of an-
timicrobial peptides (AMPs), including defensins; (Foster and
McVey Neufeld, 2013; Williams et al., 2012). Human β-defensins
have been suggested to play a role in chronic inﬂammation-asso-
ciated brain injury, a risk factor for AD. In this respect, the literature
reports (Williams et al., 2012; Welling et al., 2015) lead us to hy-
pothesize that upregulation of the production of defensins might
trigger the aggregation of amyloid in the brain.
Human α-defensins include human neutrophil peptide 1-4
(HNP1-4) and intestinal human defensins (HD-5 and HD-6),rved.
. Mándi).produced by Paneth cells. Human β-defensins make up another
family of antimicrobial peptides (Ganz, 2003; Pazgier et al., 2006).
Besides their antibacterial and antiviral effects, defensins exert
numerous immunological effects (Oppenheim and Yang, 2005;
Yang et al., 2002). While the expression of human defensin beta-1
(hBD1) is generally constitutive, the levels of human defensin beta-
2 (hBD2) are inducible by proinﬂammatory cytokines and bacteria.
Defensin genes have been mapped to 8p22-p23 (Linzmeier and
Ganz, 2005). A role of the DEFB4 gene in determining human β-
defensin-2 (hBD2) as potential modiﬁer in AD has not been hy-
pothesized previously.
We therefore considered it of interest to investigate the re-
levance of the copy number (CN) polymorphism of the DEFB4 genes
in AD. We additionally investigated the levels of human β-defensin-
2 (hBD 2) in the cerebrospinal ﬂuid (CSF) and the sera of the pa-
tients with AD. The study was supplemented with the measure-
ment of human α-defensin (Human Neutrophil Peptide 1-3; HNP1-
3) in the circulation and in the CSF.2. Materials and methods
2.1. Patients and controls
A total of 206 AD patients 69 men and 137 women, average age and standard
deviation (S.D.) 76.4274.21 years, (minimum age at onset was 65 years) were
enrolled in the study. The clinical diagnosis of AD was based on neurological and
psychiatric examinations, together with the assessment of psychometric tests to
M. Szekeres et al. / Psychiatry Research 239 (2016) 342–345 343conﬁrm cognitive impairment. Additionally, a brain CT scan or MRI was performed
in each case. All participants fulﬁlled criteria of NINCDS–ADRDA (McKhann et al.,
1984; Dubois et al., 2007). The cognitive evaluation of AD patients was based on the
AD Assessment Scale – Cognitive Subscale (ADAS-Cog) (Rosen et al., 1984; Pákáski
et al., 2012), the Mini-Mental State Exam (MMSE) (Folstein et al., 1975; Janka et al.,
1988), and the Clock Drawing Test (CDT) (Kálmán et al., 1995). To exclude pseu-
dodementia caused by depression, mood was scored via the Beck Depression In-
ventory (Beck et al., 1961),which might be a limitation (Wagle et al.,2000), but
patients with less than 12 BDI scores have only been included to the study.
The control group comprised 250 healthy volunteers 92 men and 158 women,
average age7S.D. 72.6976.82 years with normal cognition (MMSE score higher
than 28).
All cases and controls were of Hungarian ethnic origin. Informed consent was
obtained from all patients or responsible guardian in case of incapacity and con-
trols. All patients were treated in accordance with the Patient Right's Protection Act
of our institutions and according to international guidelines.
The local Ethics Committee of the Hungarian Investigation Review Board gave
prior approval to the study.
2.2. Determination of DEFB4 gene copy number (CN)
Genomic DNA was extracted from peripheral blood anticoagulated with EDTA
in accordance with the manufacturer's instructions (High Pure PCR Template Pre-
paration Kit; Roche Diagnostic GmbH, Mannheim, Germany, Cat. no: 1796828).
A TaqMan real-time PCR assay, speciﬁcally for ampliﬁcation of genomic DEFB4,
was performed as described previously (Tiszlavicz et al., 2012). Brieﬂy, quantitative
DEFB4 ampliﬁcation data were normalized to ABL [FAM-lebeled albumin (Applied
Biosystems, Cat. no. 4331182)], as a standard reference gene considered to be
present in only 2 copies in the genome. The reference gene was used as an internalAD
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and controls. Horizontal lines represents medians. Insertion: Individual variation in copstandard (Bentley et al., 2010) added to each single tube. Quantiﬁcation was eval-
uated by the comparative CT (Threshold Cycle) method (Szilagyi et al., 2006).
2.3. Determination of human β-defensin 2 (hBD2) and HNP1-3 concentrations
ELISA of hBD2 (Alpha Diagnostic San Antonio, TX, USA) was used to test for the
occurrence of the human β-defensin 2 peptide in the sera and in CSF of the controls
and patients, on the basis of manufacturer's instructions.
The HNP1-3 concentrations in the sera and CSF were determined by ELISA
(Hycult-Biotech HK324, Uden, The Netherlands) according to the instructions of the
manufacturer.
2.4. Statistical analysis
The signiﬁcance of the differences was analyzed by the Mann-Whitney test.
The GraphPad prism 5 statistical program was used for all statistical calculations
(GraphPad Software Inc. San Diego, CA, USA).3. Results
3.1. Copy number (CN) polymorphism of DEFB4
The determination of CN was performed in 206 patients in the
AD group and in 250 controls. The median CN in the controls was
4, the 75% percentile 5, and the 25% percentile was 3. In the ADAD
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25% percentile of 4; po0.001 with the Mann-Whitney test (Fig. 1
inset).
3.2. Levels of hBD2 in sera and in cerebrospinal ﬂuids (CSF)
The levels of human β-defensin 2 were determined in the sera
of 52 AD patients and 45 controls. Signiﬁcantly higher levels of
hBD2 were measured in AD patients than in the controls (Fig. 1a.).
The median levels were 265.5 pg/ml in AD vs. 169.4 pg/ml re-
spectively (po0.01).
The median levels of β-defensin 2 in the CSF of 43 AD patients
were 8.6 pg/ml vs 1.201 pg/ml in the control group (n¼40),
po0.001 Fig. 1b.
3.3. Levels of HNP1-3 (α-defensin) in sera and in cerebrospinal ﬂuids
(CSF)
The median serum concentrations of α-defensin in 43 AD pa-
tients were 147.3 ng/ml, signiﬁcantly higher than that in 40 con-
trols: 122.3 ng/ml (po0.05) Fig. 1c.
The median concentration of α-defensin in the CSF of 52 AD
patients was signiﬁcantly higher: 85.16 ng/ml than that in 40
controls: 1.23 ng/ml, (po0.001) Fig. 1d.4. Discussion
It has been postulated, that chronic infections might be initial
events in the pathogenesis of AD, which can give rise to persistent
inﬂammatory stimuli. The inﬂammatory response thereafter may
indirectly lead to the upregulation of amyloid β production
(Welling et al., 2015). Not only the levels of the inducible hBD2
were elevated in the cerebrospinal ﬂuid and sera of AD patients,
but also those of HNP1-3. Our data are in accordance with recent
ﬁndings (Watt et al., 2015), reporting that the levels of peripheral
α-defensins are elevated in Alzheimer's disease. The copy number
polymorphism of the DEFB4 gene has been reported to inﬂuence
the production of hBD2 (Linzmeier and Ganz, 2005; Hollox et al.,
2008; Jansen et al., 2009; Tiszlavicz et al., 2012). Accordingly, in
our study a signiﬁcant linear correlation was found between the
DEFB4 CN and the serum levels (p¼0.002; r2¼0.196) or CSF levels
(p¼0.001; r2¼0.222, respectively). The secretion of HNP 1-3
seems to be independent of the copy number of DEFA gene
(Németh et al., 2014), and we therefore did not investigate it.
The present study supports the view of the potential role of
antimicrobial peptides such as human α and β-defensins as pa-
thogen-targeting agents in brain infections with respect to the
pathology of AD. Whether the AD condition is the consequence of
high levels of defensins which may further induce neurodegen-
eration and Aβ formation, or the elevated levels of defensins are a
consequence of AD, is currently unknown.
Further investigations are necessary to elucidate the regulatory
functions of defensins in the pathomechanism of AD.Acknowledgement
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